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ABSTRACT 
CHANGE IN BONE MINERAL DENSITY AMONG HIGH FREQUENCY 
APHERESIS BLOOD DONORS 
 
 
Walter Bialkowski, B.S., M.S. 
 
Marquette University, 2018 
 
 
Exposure to citrate anticoagulant during apheresis blood donation induces 
significant decreases in serum ionized calcium with subsequent perturbations to 
parathyroid hormone, vitamin D, and markers of bone remodeling. Cross-sectional 
studies of bone mineral density (BMD) among apheresis donors exhibit conflicting 
results. Resolving the potential impact of the highest apheresis donation frequency 
represents a significant knowledge gap in ensuring adequate protections for volunteer 
apheresis blood donors. ALTRUYST (NCT02655055) was a randomized, longitudinal, 
controlled clinical trial designed to determine if repeated exposure to citrate through 
apheresis donation reduces BMD. Male donors, 18-65 years of age with no more than 
five previous apheresis donations and no diseases of bone or mineral metabolism, agreed 
to make ≥20 apheresis donations in the subsequent one year period. Dual-energy x-ray 
absorptiometry was performed at baseline and again after one year of participation. 
Paired t-test was used to assess change in mean BMD. Donors in the apheresis arm 
(n=26) made a median of 20 donations (range 4–22 donations) during the one-year study 
period with a mean donation interval of 17.8 days. Controls (n=15) made zero apheresis 
donations and a median of two whole-blood donations (range 0-6). Mean lumbar spine 
BMD at the end of the study period did not differ significantly from that at the beginning 
among donors in the control arm (mean change=-0.002 g/cm2, 95% CI [-0.020, 0.016], 
p=0.78), nor did it change significantly among donors in the apheresis arm (mean 
change=0.007 g/cm2, CI [-0.005, 0.018], p=0.24). Change in mean BMD at the total hip 
was not statistically significant for control donors (mean change=0.002 g/cm2, CI [-0.006, 
0.009], p=0.63) or apheresis donors (-0.004 g/cm2, CI [-0.10, 0.002], p=0.16). Tests for 
differences in proportions of donors with change in BMD exceeding the least significant 
change (LSC) at the lumbar spine (0.00743 ±0.02058g/cm2) between the apheresis and 
control arms in either a positive [apheresis 13 (50%), control 5 (33%), p=0.84] or 
negative direction [apheresis 8 (31%), control 6 (40%)] were statistically non-significant 
(p=0.87). Proportional increases [apheresis 6 (23%), control 6 (40%), p=0.25] and 
decreases [apheresis 11 (42%), control 3 (20%)] were not significantly different (p=0.15) 
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CHAPTER ONE: INTRODUCTION 
 
Apheresis blood collections produce life-saving therapies and represent an 
increasing fraction of all blood derived components in clinical use today. Approximately 
four apheresis derived platelet products were transfused in 2004 for every whole blood 
derived platelet product (1) (Table I). Six years later, the use of apheresis derived platelet 
products had increased to 10 apheresis derived platelet products transfused for every 
whole blood derived product (2). These data illustrate an increase in the demand for 
volunteer apheresis blood donors in the United States. This demand requires increasing 
the number of donors undergoing apheresis, increasing the frequency of apheresis 




Hospitals Blood Centers Total RATIO          
Apheresis : 
WBD Apheresis WBD Apheresis WBD Apheresis WBD 
2004 681 184 44 10 725 194 3.7 : 1 
2006 1,196 248 36 9 1,232 257 4.8 : 1 
2008 1,399 195 34 38 1,433 233 6.2 : 1 
2010 1,953 197 17 2 1,970 199 9.9 : 1 
Table I. Summary data from National Blood Collection and Utilization Survey Reports 
showing the number of transfused apheresis-derived and whole blood-derived (WBD) platelet 
products for participating hospitals and blood centers from 2004 to 2010.  Values are reported 






Table II shows the relationship between the number of apheresis platelet and red 
blood cell procedures performed and the corresponding number of units derived over a 
six year period in the United States (1-4). While the number of apheresis red blood cell 
collections has increased, the proportion of products derived from each collection has 
remained unchanged (53% in 2004; 49% in 2010). In contrast, both the number of 
apheresis platelet procedures and the number of units yielded per procedure had 
increased. An additional 200,000 platelet apheresis procedures were performed in 2010 
as compared to 2004; an increase of 17%. There was also an increase in the number of 
platelet product units derived from 1.3 per procedure in 2004 to 1.9 per procedure in 
2010. Optimization in manufacturing practice might have played a modest role in this 
observed increase in blood product yield per procedure; however, blood collecting 
organizations were likely increasing the number of units derived from an individual 
donation. Operationally, apheresis donor recruitment strategies often focus efforts on 
retaining donors willing to donate often and who are capable of giving multi-product 
donations in part because the number of donations in the previous year has a positive 
association with donor return (5). These patterns of apheresis blood collection emphasize 











Apheresis Red Blood Cells Plateletpheresis 
Procedures 
Performed Units Yielded 
Procedures 
Performed Units Yielded 
2004 434 †824 1,164 1,527 
2006 - 1,619 1,167 1,823 
2008 1,022 1,926 1,352 2,130 
2010 976 1,978 1,340 2,516 
Table II. Summary data from National Blood Collection and Utilization Survey 
Reports from 2004 to 2010 showing the estimated number of apheresis procedures 
performed and number of corresponding component units yielded for participating 
hospitals and blood centers.  Values are reported as thousands of units (e.g. x 103). 
†Estimate based on consultation with participating blood centers and average number 
of units produced per apheresis procedure. 
 
Apheresis red blood cell collection guidelines are based on FDA criteria for 
allogeneic whole blood donation, which mandates a minimum of eight weeks between 
single- and 16 weeks between double-red blood cell donations [21 CFR 640.3(b) and 
640.12]. Subsequent eligibility for donation is based on total red blood cell loss at the 
time of collection with a maximum loss of 1,540 mL per rolling 12 month period. Platelet 
apheresis donation guidelines are currently founded on studies showing that frequent 
apheresis platelet donors are able to maintain platelet counts within the normal reference 
range (6-8). These platelet apheresis studies supported an AABB comment and FDA 
policy increase in the number of apheresis donations an individual volunteer donor can 
make from 12 to 24 per rolling 12 month period with no lifetime maximum (9, 10). 
Federal regulations on paid source plasma donors allow 110 apheresis donations in a 
rolling 12 month period [21CFR640.65(8)]. Despite a wealth of information on the 
physiology of the apheresis donation experience, fundamental data are still needed to 
inform policy that maximizes donor health and maintains the national blood supply. 
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In contrast to whole blood collections, apheresis procedures require the use of 
intravenous (I.V.) citrate anticoagulation. Cross-sectional studies have reported that 
intermittent exposure to I.V. citrate is associated with significant declines in bone mineral 
density (BMD) (11, 12) or no changes at all (13). In contrast to I.V. citrate, oral 
potassium citrate formulations of much lower dose have been used to treat low BMD 
with well-documented efficacy (14). The impact of I.V. citrate received during apheresis, 
either positive or negative, is important given that BMD is a significant risk factor for 
low trauma fracture, a problem that affects more than two million people in the U.S. 
annually (15). The cross-sectional studies that have been performed on apheresis donors 
have important limitations that call into question the validity of the reported relationship 
between citrate exposure and BMD. Thus, it is ultimately unknown what effect repeated 
exposure to I.V. citrate has on skeletal health. As demand to preferentially transfuse 
apheresis blood products continues to increase, the importance of understanding the 




Null Hypothesis: high frequency apheresis blood donation does not cause declines in 
BMD after a one year follow-up period.  
Alternate Hypothesis: high frequency apheresis blood donation causes declines in BMD 







The objective of this project was to assess the impact of I.V. citrate exposure 
through apheresis blood donation on BMD using dual-energy x-ray absorptiometry. Our 
central hypothesis was that frequent, repeated exposure to I.V. citrate causes declines in 
BMD. Based on data from treatment of low BMD with oral citrate, we further 
hypothesized that infrequent exposure to I.V. citrate may be associated with improved 
BMD. The rationale for conducting this study was based on the need to obtain empirical 
data that will help ensure the health of volunteer donors, or, to develop protocols that 
protect members of this valuable community resource.  
Specifically, we studied two groups: 1) donors who, for the first time, begin 
undergoing a series of apheresis blood donation procedures during the follow-up period, 
and, 2) healthy whole blood donor controls. This was a randomized, controlled study. 
Blinding was achieved through the use of a blinded external reviewer of all outcome data. 
The use of the same blood donor as their own control represented a simple and validated 
approach to account for variation in BMD in the general population, thereby avoiding 
fundamental design limitations of previous cross-sectional studies. We anticipated that 
findings from this study would serve as the foundation for larger, randomized trials 
addressing the role of repeated apheresis on BMD in blood donors, or, confirm that 




CHAPTER TWO: BACKGROUND 
 
Apheresis Blood Donation 
 
In contrast to donating whole blood, making a blood donation by apheresis 
permits the collection of individual blood components such as platelets, plasma, or red 
blood cells. Despite longer average collection times, the blood collection community 
benefits immensely by allowing an individual donor to come back more frequently than 
every 56 days (in the case of platelets and plasma), decrease post-collection 
manufacturing costs, and optimizing transfusion therapy by matching donor-recipient 
attributes before a unit of blood is ever collected. Furthermore, transfusion of an 
apheresis-derived blood product minimizes recipient exposures to foreign antigens, 
thereby mitigating the risk of alloimmunization. During apheresis, whole blood exits the 
body through traditional venipuncture and is processed in an extracorporeal circuit that 
involves centrifugation, separation, and return of un-harvested blood components back to 
the donor. Normal blood coagulation would commence in this environment but is 
suppressed with anticoagulant (AC) treatment.  
Apheresis blood collection guidelines are determined at the national level. This 
has resulted in some disparities by country in terms of the maximum number of allowable 
apheresis procedures per annum by an individual as well as the minimum inter-donation 
interval by component type. Of note, there is no maximum number of lifetime donations 
an individual donor can make as long as they continue meeting local donor eligibility 
criteria. Thus, regardless of your country of donorship, you may achieve the same 
number of lifetime donations as your expatriate counterpart.   
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The current inter-donation intervals for common blood donation procedures in the 
United States are provided in Table III. The maximum amount of time between apheresis 
blood donations is a matter of personal preference, so long as that interval is no shorter 
than that permitted by local regulations. It is possible that an individual volunteer blood 
donor can make as many as 26 apheresis blood donations in a one-year period. This is 
based on the assumption that the donor makes 24 single platelet apheresis donations and 
two double red blood cell donations. The primary limiting factor in terms of the number 
of allowable donations is based on blood donor plasma volume depletion. Platelets 
require some volume of plasma for suspension before transfusion. Similarly, a double red 
blood cell product does indeed contain a very small volume of plasma. Therefore, the 
small amount of plasma removed from the body is multiplied by the relatively high 
frequency of allowable apheresis procedures and leads to donor deferral for exceeding 
donated plasma volumes.  
 
Donation Type Inter-Donation Interval (days, based on average maximum by year) 
Whole  Blood 56 
Double Red Blood Cells 112 
Plasma 30 
Platelets 14 
Table III. Comparison of the average number of days between allowable blood donation 
by donation type in the United States. Platelet donations may occur more frequently than 
every 14 days, though the per year maximum number of allowable donations in the 






The duration of an individual apheresis blood donation procedure is determined 
by a number of factors. A typical double red blood cell procedure can take approximately 
40 minutes, but this depends on factors such as the donor’s hematocrit (proportion of 
formed elements in the blood), their blood volume, as well as their ability to tolerate the 
procedure itself (16). Similarly for the collection of platelets, the amount of time that an 
individual spends donating is a function of their circulating platelet count, the number of 
component products they are donating (single, double, or triple platelet), and the ability to 
tolerate the procedure (17). A donor’s ability to tolerate the procedure is heavily 
influenced by the effects of the AC solution (18, 19). 
As whole blood leaves the site of venipuncture, citrate AC is administered before 
the extracorporeal blood enters the centrifuge housing. The amount of AC an individual 
donor receives during a given apheresis blood donation procedure depends, first, on the 
type of apheresis machine being used. There are continuous and intermittent flow devices 
used in apheresis blood collection with intermittent flow devices having slightly less total 
citrate burden to the donor (assuming all other determinants equal) (20). Because this 
disparity in citrate burden is relatively inconsequential, it is also one of the least 
important considerations when a blood collecting agency is determining which type of 
apheresis machine to use for collections. The result is that both types of machines are 
currently in use in the United States, as well as around the world. 
In addition to the type of apheresis machine, the donor’s total blood volume is an 
important determinant of the amount of AC administered during an apheresis procedure 
(21). Donors with smaller blood volumes, such as women, are not able to dilute the same 
amount of AC over as large a blood volume as their male counterpart. This corresponds 
9 
 
to an increased concentration of active AC in the blood at any given time, making women 
more likely to experience adverse side effects associated with citrate anticoagulation (22). 
This example illustrates the importance of concentration of citrate on the overall burden 
of citrate the donor experiences.  
Another determinant in the concentration of citrate in the blood is the AC-to-
whole blood ratio (AC:WB). At higher proportions of AC per unit of whole blood, 
apheresis blood collection times are decreased. The total blood collection time is also 
affected by the inlet pump rate, which in combination with AC:WB, determines the 
overall length of an apheresis procedure. Donors who can tolerate higher AC:WB ratios 
do not require as high of an inlet pump rate as a donor who is more sensitive to 
experiencing side effects associated with citrate anticoagulation. In contrast, sensitive 
donors often require a larger volume of whole blood to be processed which alters the inlet 
pump rate. The fact is that each apheresis blood collection is highly personalized and 
subject to values imputed in embedded algorithms, donor tolerance of citrate AC, and the 
overall goal of the apheresis procedure itself (i.e. the number of component products 
derived). 
Finally, the type of blood component being collected modulates AC exposure. It 
has been shown that as much as 85% of the citrate introduced in the extracorporeal circuit 
is actually diverted to the actual apheresis plasma product (23). Thus, donors making 
apheresis plasma donations are experiencing a significantly reduced citrate burden as 
compared to those who are making plateletpheresis or double red blood cell donations. 
Apheresis plasma collections represent the most common form of apheresis in many 
European countries, whereas apheresis plasma products are less frequently obtained in 
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the United States and platelet collections by apheresis are common. Therefore, any long-
term studies of the effect of AC on health outcomes in apheresis donors should carefully 




Anticoagulant citrate has been used for decades to confer protection against 
extracorporeal thrombosis during apheresis. Citrate’s mechanism of action involves 
binding ionized calcium and subsequently interrupting thrombus formation in the 
extracorporeal circuit. Many variables determine the amount of citrate an individual 
apheresis donor is exposed to, including the type and duration of an individual apheresis 
blood donation, as well as the number of lifetime donations made by an individual donor. 
Unlike many alternative AC solutions such as heparin, anticoagulation with citrate is 
superior in terms of pharmacokinetic half-life, risk of hemorrhage, and cost. Each 
molecule of citrate has three carboxylic acid subgroups that are negatively charged. As a 
result, the molecule itself confers anticoagulant properties by binding divalent metal 
cations, such as calcium, that are essential cofactors in the intrinsic clotting cascade. With 
the third carboxylic acid subgroup still ionized, complexed citrate remains solubilized in 
human blood and does not confer the risk of precipitation (24). The half-life of citrate is 
approximately 36 minutes (25). It undergoes rapid metabolism through the tricarboxylic 
acid cycle in organs rich with mitochondria such as the liver and skeletal muscle. What is 
not metabolized is simply excreted in complexed form in the distal convoluted tubule of 
the kidney nephron.  
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Exogenous citrate spends a variable amount of time in the extracorporeal circuit 
during apheresis. Nevertheless, the longest interval between administration and entry into 
the donor’s vasculature is less than ten minutes and most of the citrate is still in its active 
form. This has been shown in several studies where the concentration of citrate was 
monitored in apheresis blood donors. There is an initial surge of citrate in the donor, 
many times greater than normal biological concentrations, in the minutes following 
apheresis initiation (22, 26). The concentration of citrate continues to increase throughout 
the procedure as more cycles of blood processing occur (22, 26). As expected, the 
concentration of citrate in peripheral blood plateaus at the termination of apheresis and 
begins declining rapidly thereafter. All residual citrate is metabolized or excreted within 
the 24 hour period after the termination of AC exposure (22). 
As predicted by citrate’s mechanism of action, the concentration of serum ionized 
calcium in the donor’s blood decreases immediately upon the first return cycle of the 
apheresis machine (26). This indicates that there is active citrate that has not yet 
complexed with calcium in the extracorporeal circuit. This biologically active form of 
citrate begins to sequester ionized calcium in the peripheral circulation. Throughout the 
procedure donor peripheral blood continues to experience declines in serum ionized 
calcium concentrations to levels that are slightly below the normal healthy range (27). It 
is this decline in serum ionized calcium, as well as general blood cooling in the 
extracorporeal circuit, that is responsible for the adverse reactions experienced by 
apheresis blood donors (28). 
Rates of citrate infusion can vary, though the industry standard range for ACD-A 
and ACD-B are between 1.0 and 1.8 mL/kg/min (29). It is well documented that doses of 
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citrate used in apheresis platelet collections positively correlate with serum citrate 
concentration during apheresis procedures (22, 26, 30). Routine apheresis collection 
procedures elicit a spike in serum citrate from 0.11mmol/L (±0.04) at baseline to 
1.61mmol/L (±0.3). Because the concentration of citrate in peripheral blood is dose-
dependent (26), the derivation of multiple apheresis blood products corresponds to a 
larger dose of IV citrate in the blood donor. Citrate’s half-life in the circulation is 
approximately 36 minutes (25) and donors are able to fully metabolize exogenous citrate 
from apheresis collections within 24 hours of exposure (26, 31). 
Modern apheresis machines report the amount of anticoagulant used after 
completion of an apheresis procedure. The common range of anticoagulant volume 
administered during an apheresis procedure is 200 – 800mL. Apheresis platelet 
collections can occur very frequently, up to 26 times per year, and are increasing in both 
number and duration. Thus, it is important to consider the effects of IV citrate exposure, 




Citrate’s role as a metal chelating agent that binds divalent cations, such as 
calcium and magnesium, has been thoroughly characterized (32). Like endogenous 
citrate, sodium citrate dihydrate and citric acid in acid-citrate-dextrose (ACD) solutions 
chelate calcium ions in the blood by forming calcium-citrate complexes that disrupt 
coagulation (33, 34). Studies documenting changes in circulating divalent cation 
concentrations in apheresis blood donors have shown that there are similarities across 
donation type. In a study by Szymanski, 79 volunteer donors undergoing typical 
13 
 
apheresis procedures employing citrate anticoagulation demonstrated an average 22% 
decrease in serum ionized calcium (iCa; from 4.19 mg/dL to 3.27mg/dL) when 
comparing pre- and immediately post-procedure blood samples (30). Average decreases 
of 33% and 39% in circulating iCa and ionized magnesium (iMg), respectively, were 
observed in another study of volunteer blood donors undergoing plateletpheresis (26). 
Hester and colleagues showed that donors with a blood volume of four liters undergoing 
typical platelet apheresis procedures with citrate anticoagulation experienced decreases in 
iCa of 15% at 10 minutes and 31% at 90 minutes (27). Similar findings were reported for 
a study of healthy leukapheresis donors, where serum iCa and iMg decreased 35% and 
56%, respectively (35). Ionized calcium is a tightly regulated molecule both intra- and 
extracellularly. Donors generally tolerate decreases in concentrations of iCa up to 20% 
before experiencing side effects (36) with women having a greater sensitivity to declining 
concentrations than men (22).  
Figure I provides a simplistic diagrammatic representation of the movement of 
calcium throughout the body in a prototypical, healthy, adult individual over the course 
of one day. Much of the 1,000mg of ingested calcium from food is excreted in the feces. 
The 200mg net gain of calcium from the G.I. tract is lost in the urine. Calcium from 







Figure I. The movement of total body calcium throughout the course of 
one day in a prototypical, healthy, adult individual whose calcium status is 
in balance. 
 
G-protein coupled receptors on the surface of the parathyroid glands and kidneys 
directly sense declines in iCa concentration in the blood and stimulate secretory cells to 
release parathyroid hormone (PTH) (37). Alterations to blood ionized calcium 
concentrations are carefully monitored in the body due to calcium’s central role in many 
biological functions. Monitoring occurs at the parathyroid glands; four pea-sized 
structures immediately adjacent to the thyroid gland at the base of the neck. G-protein 
coupled receptors, the calcium sensing receptors (or CaSR), located on the surface of 
chief cells are bathed in peripheral blood. In the absence of sufficient ionized calcium, 
these proteins change conformation and rapidly trigger the synthesis of PTH (37). The 
secretion of PTH into circulation is extremely rapid and can occur within minutes of a 

















concentrations of ionized calcium in the bloodstream, we anticipate high circulating 
concentrations of PTH as illustrated in Figure II. 
 
 
Figure II. Schematic representation of the stimulus, decreased ionized 
calcium in the bloodstream, affecting the secretion of PTH by the 
parathyroid glands. 
 
PTH has three primary effector organs in the body and all are associated with 
replenishing the supply of ionized calcium in the bloodstream (Figure III). In the kidneys, 
PTH directly stimulates the reabsorption of filtered calcium in the nephron. PTH also 
stimulates 1-α hydroxylase that ultimately converts 25-hydroxy (OH) vitamin D to the 
active metabolite 1, 25 di-hydroxy ((OH)2) vitamin D. Increasing 1, 25 (OH)2 vitamin D 
levels upregulate calcium ATP-ase channels in the intestinal epithelium and promote 
calcium absorption. Finally, PTH stimulates osteoblasts to secrete the ligand for receptor-
activator of nuclear factor kappa B (RANK-L) that, along with macrophage colony 
stimulating factor (MCS-F) lead to the terminal differentiation of hematopoetic 
precursors to active osteoclasts. Active osteoclasts liquefy the bone matrix through a 
process called resorption. Hydrochloric acid dissolves the mineral-rich hydroxyapatite 














Figure III. The relationship between effector organs of secreted PTH and 
their role in replenishing low ionized calcium in peripheral blood. 
 
PTH directly stimulates the reabsorption of filtered calcium in the kidney 
nephron. Renal control of reabsorption is under both osmotic and electrochemical 
control. Calcium is a divalent cation that can be specifically regulated in the kidney 
through the manipulation of the electrochemical gradient. Selective reabsorption of 
calcium requires that positively charged molecules be excreted in order to maintain 
balance. In the case of hypocalcemia, the nephron is stimulated by PTH to reabsorb the 
positively charged cation. In exchange, the body excretes positively charged phosphate 
ions into the filtrate leading to phosphaturia. 
The influence of continuous exposure to citrate on the release of PTH was 
assessed in 12 healthy donors undergoing platelet apheresis donation in a study by 

















within 5-15 minutes of the start of citrate infusion (38). This has been corroborated in a 
number of platelet apheresis donor studies (11, 26, 31, 39). Initial PTH surges in 
apheresis donors are short-lived and PTH concentration returns to near-baseline as early 
as 30 minutes after the infusion of citrate is terminated (26, 39). One study has shown 
that PTH may remain elevated up to one day after the procedure despite a termination in 
exposure (11).  
The release of PTH into circulation simultaneously triggers all three of the body’s 
main mechanisms to restore normal iCa: increased calcium reabsorption in the distal 
tubules of kidney nephrons, increased intestinal calcium absorption through a Vitamin D 
mediated pathway, and increased bone resorption (Figure III). Increases in serum PTH 
increase calcium reabsorption in the distal convoluted tubule. Citrate exposure through 
apheresis, however, increases urinary loss of calcium (40) despite concomitant increases 
in PTH. Loss of calcium in the urine has been shown to be citrate dose-dependent (26) 
and occurs during the 24 hour period after exposure to citrate (31, 35). Calcium 
reabsorption in the kidney is 98% efficient under normal conditions, suggesting that 
replenishment of iCa losses during apheresis will be minimal. 
PTH also stimulates the activation of Vitamin D, which in turn increases intestinal 
absorption of calcium. For platelet apheresis donors, concentrations of activated Vitamin 
D have been shown to decrease 9% from baseline immediately after standard platelet 
apheresis. One day following the exposure to citrate, activated Vitamin D exceeds 
baseline concentrations by an average of 26% (31). Through a Vitamin D mediated 
pathway, some calcium can be replenished in apheresis donors through small intestine 
absorption (37). But despite providing large amounts of calcium as supplements, this 
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study showed that donors were not able to recover 100% of baseline iCa concentrations 
through this mechanism. Furthermore, calcium supplementation is, in practice, symptom 
dependent and not routinely employed outside of the setting of this particular study. 
Thus, the apheresis donor’s body may rely on metabolically active trabecular bone to 
recoup lost calcium. 
Bone Remodeling 
 
 Bone is a biological structure comprised of relatively few cell types and 
associated proteins. However, terminal differentiation of these cell types coupled with 
incessant metabolism make the human skeleton an incredibly dynamic human tissue. This 
constant evolution of organic matrix and mineral underpin the essential role of the human 
skeleton in human structure and function. Homeostasis of the human skeleton is 
determined by the cell types whose changing roles determine the various types of bone. 
Osteoblasts play the role of secreting organic proteins that form the structure upon which 
mineral apatite deposits. Alterations to osteoblast function affect the skeleton by 
decreasing its density and ability to resist fracture. Bone resorbing osteoclasts serve the 
crucial role of helping to maintain systemic mineral homeostasis, but can cause 
significant problems with skeletal integrity if disproportionately activated. Few studies 
have explored the impact of apheresis on skeletal remodeling. 
 Bone is in a constant state of remodeling that is a coupled process linking the 
resorption of bone by osteoclasts and the deposition of new bone by osteoblasts. The 
deposition of bone is performed by osteoblasts: mesenchymal stem cell-derived cells 
under the master regulation of RUNX-2 (41). Bone deposition involves the secretion of 
the organic matrix elements of bone, namely Type 1 collagen, by osteoblasts on the 
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surface of bone. Collagen assembles into helical fibrils that form cross-links leading to an 
overlapping structure. The alignment of collagen fibrils is offset, leaving a small 
proportion of the fibril exposed and creating a potential nucleation site for mineral 
deposition (42). Mineral deposition is spontaneous and involves substituting subgroups of 
the hydroxyapatite molecule with various minerals which lead to the creation of apatite. 
Osteoblasts either undergo apoptosis, or, are embedded within the newly formed matrix 
and undergo terminal differentiation to osteocytes. 
 The interplay between bone resorption and deposition is so tight that indeed, the 
very cells that deposit bone are essential to the stimulation of the cells that resorb it. 
Upon stimulation by various cytokines, osteoblasts secrete the ligand for receptor 
activator of nuclear factor kappa B (RANK-L). RANK-L, along with macrophage colony 
stimulating factor (MCS-F), bind receptors on hematopoetic osteoclast precursors 
stimulating fusion, multinucleation, and differentiation into osteoclasts. These very large 
cells form a tight bond on the surface of bone called the sealing zone. Hydrochloric acid 
is subsequently secreted to dissolve the mineral element of bone, apatite (43). Apatite is 
rich in important minerals such as calcium and magnesium. Cathepsin K is also secreted 
(44), leading to the breakdown of type 1 collagen, the primary organic component of 
bone. Osteoclast plasma membranes express a unique morphology during this process by 
forming highly convoluted festoons called the ruffled border that increase the surface 
area of the cell maximizing the absorption of the newly liquefied components of bone 
(45). Migration of these components through the cell and into peripheral circulation 




In addition to secreting osteoclast stimulating factors, osteoblasts secrete a decoy 
receptor protein called osteoprotegerin. This decoy receptor can sequester otherwise 
potent activators of osteoclast differentiation (46). In effect, osteoblasts have complete 
control over osteoclast activation by manipulating the relative concentrations of these 
substances in the immediate proximity of active bone metabolism. This known 
phenomenon may represent an optimal therapeutic target for diseases of osteoclast over 
expression, however, RANK-L is non-specific and such therapies could have significant 
off-target effects. 
There are several markers of bone resorption, however only a few have been 
measured in apheresis donors. C-terminal telopeptides, such as β-CTX, are both sensitive 
and specific measures that quantify the breakdown of type 1 collagen (47). In a 
randomized, placebo-controlled study of blood donors, citrate infusion increased serum 
concentrations of β-CTX in apheresis donors whereas controls not receiving citrate had 
no change in their serum β-CTX (p < 0.0001 for between-exposure comparisons) (48). 
This finding held true for donors in another study where both serum and urine 
concentrations of β-CTX were elevated by as much as 26% and 17%, respectively, and 
remained elevated for up to 24 hours post-donation (11). The greatest measured increases 
in β-CTX have been observed at the completion of an apheresis procedure (48) 
suggesting that bone resorption begins during exposure to citrate. When concentrations of 
β-CTX are compared to concentrations of osteocalcin (OC), a protein secreted by bone-
forming osteoblasts, the proportion of these two markers throughout the procedure 
increases suggesting that bone metabolism may shift toward resorption during apheresis.  
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Additional data in the weeks following apheresis are needed because formation occurs at 
the end of the remodeling cycle. 
Phosphate is also an essential component of hydroxyapatite in bone. As elevations 
in PTH stimulate the dissolution of hydroxyapatite by osteoclasts, release of phosphate 
from bone increases. PTH simultaneously reduces reabsorption of phosphate ions in the 
proximal convoluted tubule of kidney nephrons, allowing excess phosphate to be 
excreted and ensuring that concentrations of serum phosphate do not exceed normal 
physiologic concentrations. Serum phosphate concentrations decrease modestly during 
apheresis and return to pre-apheresis concentrations within the 24 hour period following 
apheresis (11). However, the concentration of fibroblast growth factor (FGF) 23, the 
protein that stimulates the expression of sodium-phosphate co-transporters in the 
nephron, has not been measured in apheresis blood donors. 
There is some evidence that exposure to citrate from apheresis actually favors 
bone deposition, not resorption. OC has been shown to remain slightly elevated at 24 
hours post-apheresis donation (31). Furthermore, concentrations of osteoprotegerin 
(OPG), an inhibitor of the maturation of bone degrading osteoclasts, were observed to 
decrease following 120 minutes of citrate exposure and recover to baseline at 24 hours 
post-exposure (11). Tartrate-resistant acid phosphatase (TRAP), an enzyme expressed by 
osteoclasts, has been shown to be a useful marker of bone resorption because of its 
limited variability in vivo (49, 50). In apheresis platelet donors TRAP was observed to be 
lower than baseline at both 120 minutes and 24 hours post-exposure suggesting that 
apheresis acutely suppresses bone resorption. The authors do not address the paradoxical 
nature of this finding, especially considering their claim that a finding of lower bone 
22 
 
density in apheresis donors relative to controls is a “true finding”. It should be mentioned 
that a limitation of using TRAP to assess bone resorption in healthy people may be the 
inability to make meaningful interpretations when threshold concentrations below that of 
pathological conditions are not met (51).  
The process of remodeling bone is a process that occurs over a 4-6 month period. 
The availability of physiological data in apheresis blood donors spanning an inter-
donation interval of two weeks is relatively sparse. Rather than creating a complete 
profile of prolonged effects of IV citrate exposure in apheresis donors, researchers have 
begun looking into bone-related health outcomes. Consequently, the opportunity exists to 
fully catalog apheresis blood donor physiology in the weeks following IV citrate 
exposure. With some studies showing evidence of bone remodeling 14 days after 
exposure to citrate (52), it is difficult to use the available data to predict long term effects 
on bone health in this donor population. More careful characterization of the effects of 
exposure duration, and especially frequency, is needed as the body’s recovery following 
exposure has not been sufficiently studied.  
Steddon and Cunningham (53) noted in their review of calcium receptor 
manipulation therapies that short periods of elevated PTH favor bone formation by means 
of expediting the maturation of osteoblasts. Further, it has been conceptualized that large 
and rapid increases in PTH followed by normalization, such as that stimulated by 
calcilytic drug therapies, may translate in bone-anabolic effects (54). Finally, we should 
not ignore that oral potassium citrate is a common treatment for low bone density with 
documented efficacy (14). Thus, intermittent exposure to citrate through apheresis blood 
donation could theoretically have beneficial effects on bone. The conclusions of many of 
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these studies have been derived from clinical trials of postmenopausal women only, all of 
whom have declining estrogen. Because of estrogen’s central role in bone metabolism, 
the generalization of these findings to apheresis blood donors warrants very careful 
attention and additional research. 
Citrate anticoagulation affects calcium homeostasis which underlies the concern 
about potential declines in bone density. Possible long-term health effects of IV citrate 
exposure during apheresis may have important implications given that decreased bone 
density is a significant risk factor for low-trauma fractures. If repeated citrate infusion 
during apheresis procedures adversely affects bone density, it is likely that the frequency 
and/or amount of citrate exposure correlate with the severity of bone catabolic effects. 
Results from a bone density study of 102 apheresis platelet donors with a lifetime average 
of 85 apheresis procedures (range 16 – 633) as compared to non-blood donor controls 
demonstrated significantly lower bone density at the lumbar spine (Z-score P=0.038) for 
apheresis donors as compared to controls (11). No significant differences in bone density 
were seen at the hip and femoral neck (Z-score P=0.36 and P=0.72, respectively). The 
authors conclude that donor-specific differences in bone metabolism are unlikely, but that 
these donors differ in the way they regulate mineral homeostasis when challenged 
metabolically by exposure to citrate. It is not clear if the authors intend this to be a donor-
specific predisposition or some type of response-mediated adaptation to citrate exposure. 
Given that the available data suggest that disturbances to the body’s homeostatic 
maintenance of bone may span the inter-donation interval of frequent apheresis donors, 
effects on bone density in high intensity apheresis donors could be sizable. However, the 
most important limitation of this study was in the cross-sectional evaluation of BMD 
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which the authors acknowledge. Because individuals achieve different peak bone 
densities, longitudinal comparisons using donors as their own controls are essential to 
drawing accurate conclusions about citrate exposure through apheresis and BMD. 
Two complimentary studies have examined the effect of repeated apheresis blood 
donation and bone-related health outcomes. The first is a prospective National Institutes 
of Health study that incorporates a longitudinal assessment of bone density 
(NCT00073060). No data are as yet available. The other study was conducted on the 
Scandinavian Donations and Transfusions (SCANDAT) database (55). This retrospective 
cohort study (56) provided the first large-scale data on the effects of frequent and long-
term apheresis donation on the risk of fractures. In this study, all available data on 
Swedish blood donors who experienced one or more apheresis blood donations during the 
period 1990 through 2012 were analyzed until death, emigration, or the end of the follow-
up period. Donor fractures were sourced from the Swedish patient register and classified 
according to the International Classification of Diseases, Revisions 9 and 10. Fractures, 
including all and osteoporosis-related fractures, were analyzed and correlated with 
apheresis blood donation using Poisson regression. There was no association between the 
number of lifetime apheresis donations, the recentness of apheresis donation, nor gender 
or age on a blood donor’s risk of fracture in any analyses. The Swedish blood donor 
population is different from the U.S. blood donor population in terms of race, ethnicity, 
body mass index, and other determinants of bone density. Furthermore, the vast majority 
of apheresis donations made during the analysis period were plasma donations where 
citrate burden to the donor is as much as 85% reduced compared to platelet apheresis 
donations (23). These large-scale epidemiology studies have previously shown utility in 
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examining potential associations between the blood donation activity and long term 
health outcomes (57-60), however, these studies are observational in nature only. Thus, a 
longitudinal, randomized study is needed in blood donors to assess whether or not 
repeated apheresis is associated with declines in bone mineral density. 
Conclusions 
 
The collection of blood products using apheresis technologies has been increasing over 
the previous decade. Citrate anticoagulation confers protection to the donor by 
sequestering ionized calcium in the donor’s blood stream. Parathyroid glands sense the 
decline in ionized calcium in donor serum and secrete parathyroid hormone. The 
physiologic response to parathyroid hormone has been measured in blood donors 
undergoing apheresis and there are indications that bone homeostasis is perturbed. There 
are very limited longitudinal data on whether or not apheresis-induced modifications to 




CHAPTER THREE: ALTRUYST Methodology 
 
In this prospective, longitudinal, randomized, controlled clinical trial 
(NCT02655055) we tested the hypothesis that high frequency apheresis donation is 
associated with declines in BMD after a one year follow-up period. Eligible donors who 
had made no more than five apheresis blood donations in the past were enrolled using 
informed consent (Appendix 1). All donors also agreed to make close to the maximum 
number of allowable volunteer apheresis blood donations during the follow-up period 
(n=26) to help limit attrition and control for potential selection biases. Dual-energy x-ray 
absorptiometry (DXA) was performed at baseline for all enrolled men aged 18 to 65 
years who had no known skeletal medical conditions. Following DXA, donors were 
randomly assigned to continue with their apheresis donation program (‘treatment’), or, 
control (no apheresis blood donation during the follow-up period). Individual subjects 
also served as their own controls through repeated measures analysis (baseline and 
approximately twelve months later). The primary outcome measure was the change in 
total lumbar spine bone mineral density as assessed by DXA. A secondary outcome 
measure included change in total hip bone mineral density. Two additional outcome 
measures included femoral neck BMD and the trabecular bone score, a gray-level textural 




This was a prospective, randomized, single-center study that assessed the effect of 
high frequency intravenous citrate exposure on bone density in volunteer apheresis blood 
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donors. Eligible participants were male, 18-65 years of age, with no more than five 
lifetime apheresis blood donations. There are known side effects of apheresis including 
paresthesia (due to hypocalcemia) and chills that deter future donation. Thus, this study 
recruited male donors who had made at least one previous donation to help mitigate 
attrition. All eligible participants were recruited from a population of donors beginning 
an apheresis blood donation program. Donors were encouraged to donate nearly the 
annual maximum of 24 donations per year (i.e. 20 – 26 donations during the study). 
Apheresis donation procedures included platelets, red blood cells, plasma, and multi-
product donation types. All donation types were allowable in the present study because 
citrate anticoagulation is universally administered, procedure times are comparable, and 
even modest amounts of citrate exposure are associated with supraphysiologic spikes in 
parathyroid hormone.   
 




• eligible volunteer blood donor 
• ≥ 18, and, ≤ 65 years of age at enrollment 
• ≥ 1, and, ≤ 5 prior apheresis blood donation procedures 
Exclusion criteria 
• Female 
• Age < 18 or > 65 years at enrollment 
• ineligible for whole blood donation 
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• BMD Z-score <(-2.0) or >(2.0) at any measurement site upon baseline assessment 
• metal prosthesis at measurement site 
• weight > 300 lbs (136 kg) 
• previous fracture of the lumbar spine or hip (femoral neck, intertrochanteric hip) 
• any fragility fracture, defined as a fracture resulting from a fall of standing height 
or less, during adulthood (specifically ≥18 years of age at the time of fracture) 
• previous lumbar spinal fusion surgery 
• cystic fibrosis 
• emphysema 
• celiac disease 
• Crohn’s disease 
• Current or past (>1month duration) use of medications known to affect BMD 
including, not limited to: 
• (phenytoin, phenobarbital, corticosteroids) 
• Current Osteoporosis Medication use including, but not limited to: 
• (Forteo, oral biphosphonates, Reclast, Prolia, calcitonin) 




The primary outcome measure was change in BMD and therefore, each 
participant served as their own control. Additionally, this was a randomized study. 
Eligible participants were randomly allocated to exposure (high frequency apheresis) or 
control (no apheresis allowed; whole blood donation allowed). Randomization occurred 
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after informed consent and baseline assessment but before the first ‘on-study’ blood 
donation. The control group was included in this single-center study design to ensure that 
any regional changes in BMD among the larger population could be detected and 
accounted for in the analysis. 
 
Recruitment and Enrollment Methods 
 
This study used a four-tiered recruitment program that aims to capture donors at points of 
intake.  
Tier 1: In-Person Strategies:  
 
Recruitment strategies used in prior studies involving face-to-face encounters 
have proven to be one of the most highly productive methodologies employed, especially 
for targeted donor groups (e.g. PR00022441, PRO00023331, PRO00022435). We 
therefore employed similar strategies in this protocol using face-to-face recruitment 
methods and an informational flyer (Appendix 2). Subjects were recruited in person by 
research staff at fixed or mobile collection sites. Research coordinators primarily 
approached donors at the time of registration following routine procedures for research 
with volunteer blood donors. Donors expressing a lack of interest in participation were 
thanked. Donors expressing interest in participating participated in further discussions 
about the study with a trained research coordinator using the informed consent to guide 
talking points. The researchers collaborated with local site managers to ensure that 
recruitment activities did not interfere with BloodCenter of Wisconsin operations and 
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donor intake. In collaboration with BCW Donor Group Recruiting, in-person recruitment 
also occurred at mobile blood drives. The overall success of this study was based on the 
team's ability to recruit new apheresis donors who were beginning to undergo these 
procedures. To improve efficiency and accuracy of recruitment efforts, as well as 
avoiding recall bias on the part of the donor, the research team requested an appointment 
list from IT/IS for eligible donors scheduled to donate at sites where in-person 
recruitment is planned. The appointment list included donor name, date of appointment, 
location of appointment, time of appointment, donor gender, number and type of 
donations in the previous 24 months, and donor ID. This list was distributed only to those 
research staff that are trained and certified in managing human subjects research related 
identifiers. Donors on the list were approached using the same strategy as for any other 
donor approached in person. These lists were maintained on the BloodCenter of 
Wisconsin secure server and any printed copies were kept in a locked file cabinet at the 
Blood Research Institute.  
To enhance the functionality of the informational flyer, the research coordinator 
collaborated with leadership in Donor Services and Volunteer Services Departments to 
identify ‘study champions’ at each fixed blood center location. Through didactic and 
interactive workshops led by the study team, endemic blood center staff and volunteers 
learned which donors were potentially eligible for the study and offered to put donors in 
touch with members of the research team. Study champions served the dual purpose of 
enhancing recruitment and maximizing data integrity by serving as a trained liaison. 
Donor Services personnel placed an ALTRUYST sticker on the donor’s summary sheet 
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to help Volunteers identify which individuals in café were potentially eligible for the 
study. The word “ALTRUYST” was all that appeared on this sticker. 
Ultimately, the research coordinator performed study screening before enrollment to 
ensure the highest degree of protocol compliance. 
Tier 2: Targeted, Active Strategies 
 
BloodCenter of Wisconsin fixed donation centers track apheresis donations made 
by individuals using a hanging file folder identified by the donor’s name. Within the 
folder is a record of the number of apheresis donations and procedure run sheets. A 
donor’s initial apheresis donations are captured in a similar way but are arranged 
alphabetically in a shared hanging file folder. Both of these resources provided an 
opportunity to tailor recruitment strategies to eligible male donors. The Tier 2 recruitment 
strategy allowed the research team to review these records for eligible subjects on site. 
Each time an eligible donor was identified the research team member placed a study card 
(business card designed specifically for the study) on the donor’s record. This practice 
cued front line staff members to provide the donor with the informational flyer 
(Appendix 2) upon presentation. Donor staff then put the donor in contact with the 
research team or the donor could have chosen to self-identify at a later time. This 
approach ensured anonymity and consistent recruitment messaging. 





This strategy was implemented using an ongoing apheresis conversion initiative 
led by BloodCenter of Wisconsin to expand the apheresis blood donor base. Beginning in 
the spring of 2015, all whole blood donors were being evaluated for their capacity to 
donate apheresis platelets. Automated reports were be generated from endemic 
BloodCenter of Wisconsin data systems to identify donors who initiated apheresis 
donation in response to this operational recruitment strategy. Targeted strategies for 
recruitment included mailings and emails at both fixed and mobile blood drives. The text 
for mailings and emails were provided as attachments to the protocol (Appendix 3). 
Additionally, BCW Call Center scripts were developed and integrated with endemic 
direct and automated appointment tools. Messaging content was derived from text 
provided in Appendices 2 and 3 because of the dynamic nature of donor recruitment 
strategies.  
These population-based approaches to sampling are subject to non-participation 
bias (i.e. eligible donors who choose not to enroll). Due to the relatively low proportion 
of donors who would have converted to an apheresis donation regimen and the relatively 
short enrollment period, all interested and eligible donors were enrolled in the study (i.e. 
no random sampling). 
Tier 4: Non-targeted, Passive Strategies 
 
The research team provided ALTRUYST informational flyers (Appendix 2) to 
BCW Donor Services Managers who posted them in blood center common areas. 
Interested subjects could then self-identify their interest in participating by either calling 
the research hotline or emailing clinicalresearch@bcw.edu. Front line blood collections 
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staff received training from Donor Services Managers (who will receive training from the 
research team) to answer any questions about the study from donors by providing contact 
information for the research team to ensure that consistent messaging occurs. Study 
champions augmented the supervisor’s need to provide information by serving as a 
trained liaison. 
Finally, the BCW website (www.bcw.edu) has modalities that directly support 
clinical trial recruitment. Using text blended from across other IRB-approved media 
(informational flyer, email script, letter) the research team collaborated with corporate 
web developers to create electronic capture mechanisms (hyperlinks) that were displayed 
broadly across research oriented web content (BCW domain only). These links were 
intended to funnel self-identifying individuals to direct contact with the research team 






Subjects who provided written authorization for participation first completed a 
survey to confirm eligibility and to evaluate increased risk of fracture including questions 
on race, ethnicity, family history of osteopenia/osteoporosis, family history of fracture, 
personal history of fracture, daily calcium intake, activity level, medication use, and other 
parameters that affect baseline BMD prior to DXA [Appendix 4]. These are considered 
standard of care intake questions for patients being evaluated for osteopenia/osteoporosis 
contributing to the validation of risk factors, with and without bone density 
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measurements, to improve accuracy of fracture prognostication tools. The survey was 
administered twice: once prior to the baseline assessment and once prior to the final 
assessment. The paper-based survey was self-administered by the study subjects and was 
reviewed by research staff to ensure complete capture of the required information. The 
survey was designed to capture responses affecting a donor’s eligibility in the study and 
therefore, donors who were ineligible based on responses did not have baseline DXA 
performed.   
Bone Mineral Density 
 
After informed consent and before the first on-study blood donation, participants 
had dual energy x-ray absorptiometry (DXA) performed [see Appendix 5]. DXA assesses 
BMD by way of emitting two fan beam x-ray energies that quantify bone density in 
mg/cm2. Baseline BMD measurements were collected before the first on-study donation 
using DXA at the lumbar spine (L1 – L4), left and right hip (femoral neck, greater 
trochanter, and intertrochanteric region), and full body using standardized equipment. 
Subjects with metal prostheses and/or prior fracture at any measurement site were not 
eligible for participation because of interference with BMD measurement. Likewise, 
subjects weighing more than 300 pounds were not eligible due to DXA scan table mass 
limits. Subjects with a fragility fracture, defined as any fracture from a fall of standing 
height or less, during adulthood (i.e. ≥18 years of age at time of fracture) were also 
excluded. 
DXA systems, as with all measurements, introduce a form of variation implicitly. 
This study used the GE iDXA™ with Encore version 11.40.004 software for all DXA 
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measurements. This machine was maintained according to manufacturer specifications 
which included periodic phantom scans, visual inspection of phantom scans, phantom 
scans after any service, and service logs.  A recent study reported the greatest numerical 
difference in BMD at the total hip for same-subject assessments at 0.007g/cm2 (62). 
Calibration data were collected for the measurement instrument and normalized prior to 
data analysis. This instrument is located in the Department of Physical Therapy, Cramer 
Hall, Marquette University, Milwaukee, WI.  
Individual bone density results can be standardized to population values for 
subjects of the same age, sex, and race and will be reported as Z-scores. Due to ethical 
considerations, any subject with a BMD Z-score <(-2.0) or >(2.0) at any measurement 
site during the study was notified of the finding [Appendix 6] and advised to seek 
medical attention. It is likely that these subjects, upon medical consultation, would begin 
an efficacious treatment regimen that would have an impact on follow-up BMD values. 
While excluding BMD outliers limits the generalizability of this study’s findings, the 
strategy employed has the advantage of addressing the question of how the vast majority 
(~95%) of eligible donors respond while eliminating possible confounding introduced by 
therapy prompted by abnormal BMD findings. Ongoing monitoring of the true 
prevalence of this finding in this study’s sample during the enrollment period was 
performed. Because the prevalence of baseline BMD out of this range was higher than 
expected, the final enrollment sample size was adjusted to achieve the desired analytic 
sample size. 
All BMD test results outside of this range, or within 0.1 standard deviations, were 
reported to this study’s Medical Monitor, Dr. Robert D. Blank, who is a clinical expert in 
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metabolic bone disease (see Section PROTECTION AGAINST STUDY RISKS). To 
preserve blinding, all BMD measurements (baseline and follow-up) were sent to an 
external adjudicator, Dr. Joseph Shaker, a clinical expert in metabolic bone disease, at the 
end of the study but before analysis. All BMD reports were blinded in terms of subject 
randomization and date of scan. The adjudicator thus served the role of interrogating all 
BMD scans to ensure quality and validity of study values. Finally, cross-calibration of 
multiple DXA systems was not required in this study because only one instrument was 




Enrolled participants had peripheral tubes of blood collected both pre- and post-
apheresis. Collection of these samples did not require an additional venipuncture because 
it was diverted from normal blood collection kits. All specimen processing was 
conducted in designated laboratories at BCW by trained personnel. Laboratory testing 
was performed at ARUP clinical research laboratories in Salt Lake City, UT. Results 
from testing were used only for the purpose of post hoc analysis and hypothesis 
generation. Analytes included elements of a comprehensive metabolic panel, testosterone, 
parathyroid hormones, complete blood counts including reticulocytes, and markers of 
bone and mineral metabolism. Laboratory testing occurred in batches well after specimen 
acquisition, and therefore results were not shared with participants at any time. Frozen 
aliquots were stored at BCW for up to three years after the study is closed to allow time 





BloodCenter of Wisconsin utilizes anticoagulant citrate dextrose solution (ACD-
A) for the collection of apheresis products. Sodium citrate dihydrate is derived from 
anhydrous citric acid (C6H8O7) and together these constitute 2.2g and 0.73g per 100mL 
of the ACD-A formulation used during apheresis, respectively. Data on ACD-A exposure 
is captured on apheresis run sheets the blood center. Table IV shows the citrate exposure 
endpoints (time of exposure, dose) that were collected for this study.  
The type of apheresis donation being made (platelet, red cell, plasma, or multi-
product), volume of ACD-A (mL) infused, and duration of apheresis procedure (minutes) 
was abstracted from blood center flow sheets for each visit over the study period. Platelet 
product yield was classified as single (3.1 – 6.6 x 1011), double (6.7 – 9.9 x 1011), and 













CITRATE EXPOSURE ENDPOINTS 
Collections Information 
Machine Trima, Amicus 
Run Sheet Yes 
Concurrent Products1 Yes 
Exposure Time 
Start Time Yes 
End Time Yes 
Total Time Yes 
Citrate (AC) Parameters 
Type of AC2 ACD-A 
[AC]3 Yes 
Lot # Yes 
Expiry Yes 
Volume AC Used Yes 
Volume AC in PLT Yes 
Actual Volume 
Infused4 Yes 
Yes = collected regularly on blood center apheresis flow sheets 
1 Concurrent plasma collection is allowed. 
2 AC = anticoagulant 
3 concentration of AC 
4 = VAC used – VPLT AC 
Table IV. Availability of citrate exposure endpoints collected from BloodCenter 




Participation in this study was time and travel intensive. At two time points 
(baseline and final visits) donors traveled to Marquette University’s campus to have bone 
density scans performed. Because of the large geographic catchment area of BCW, study 
participants received $50 per visit (no more than $100 total) to cover travel costs (Figure 
IV). Additionally, participants were offered full body composition analysis reports (at the 
end of the study only) upon request.  Throughout the study donors were asked to comply 
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with many guidelines including blood donation types, blood donation frequency, fracture 
reporting, questionnaires, and study visits. Study participants were evaluated for protocol 
compliance at the time of the final visit. Compliance with all of the study’s guidelines 
and completion of all study visits resulted in payment of $100 and $250 by check for no 
apheresis and apheresis groups, respectively. Total remuneration did not exceed $200 for 
donors in the control group and $350 for donors in the apheresis group. Compensation 
was not tied to blood donation, but solely for the clinical assessment and completing 
research study protocol(s). Please refer to the Final Appointment Letter (Appendix 7). 
To proactively address any issues that may arise between the voluntary attribute 
of the derived blood component products and study participation, the research team 
contacted the FDA’s Center for Biologics Evaluation and Research (CBER) Office in 
February 2016. The remuneration plan outlined above was presented alongside the open 
question as to whether or not component products could be labeled as “voluntary units” 
(21 CFR 606.121(c)(8)(v) and Compliance Policy Guide 230.150, Blood Donor 
Classification). The response received from FDA indicates that this remuneration plan is 





Figure IV. Participation schematic for ALTRUYST participants including amounts of 
subject remuneration based on study completeness.  
Statistical Methodology 
 
The hypothesis tested was that high frequency apheresis would cause a decline in 
BMD from baseline assessment to follow-up. Specifically, the null hypothesis was that 
for men aged 18 - 65 years and otherwise satisfying eligibility criteria, there would be no 
difference in the magnitude of change in bone mineral density between a baseline and 
follow-up bone mineral density assessment for high frequency apheresis donors (Ho: μX 
= 0, where X is change in BMD). The alternate hypothesis was that men aged 18 - 65 
years and otherwise satisfying eligibility criteria would experience a decline in BMD 
between a baseline and follow-up assessment following one year of high frequency 
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apheresis (Ha: μX < 0). The T-test statistic was used to compare change over the one year 
period in comparison to zero, or no change. This was a randomized study and the control 
group did not donate apheresis blood products during the follow-up period. The null 
hypothesis for comparing the treatment group (high frequency apheresis group) to this 
control group was that change in BMD was no different between the treatment and 
control groups (Ho: μX = μY, where X was change in BMD in the treatment group and Y 
was change in the control group). The alternate hypothesis tested was that change in the 
treatment group was greater in magnitude than change in the control group (Ha: μX < 
μY). 
There is natural variation in an individual’s peak BMD (63). This source of 
variation plays a role in the derivation of power. NHANES 2009 – 2010 examination data 
were used in estimating the mean and standard deviation of total lumbar spine BMD for 
men aged 25-50. NHANES is a stratified, multistage probability sample of the civilian 
non-institutionalized population of the United States. Data are freely available on the 
Centers for Disease Control and Prevention website: 
http://www.cdc.gov/nchs/nhanes/nh3data.htm. 
The demographic and examination data sets were downloaded from NHANES in 
April 2015. Using R, the two data sets were merged using sequence number (seqn) as the 
linking variable. Using R studio, females were excluded using the gender variable 
(riagendr); men aged <25 or >50 were excluded using the age variable (ridageyr); 
Caucasian, non-Hispanic men were selected using the race/ethnicity variable (ridreth1). 
Mean (1.054925 gm/cm2) and standard deviation (0.1345117 gm/cm2) of total lumbar 
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spine BMD (dxxosbmd) was then computed from the restricted data set. The complete 




An in vivo precision assessment of the individual technologist performing all bone 
mineral density scans in this project was performed in August of 2015 (lumbar spine) and 
again in July 2017 (total hip). Precision assessment was performed per ISCD guidelines 
(64). In summary, 15 patients were scanned on the same DXA machine thrice with 
repositioning in between assessments. Eligible participants were male, between 18 and 65 
years of age, generally healthy and otherwise eligible for the research study. Precision 
assessment was performed on the lumbar spine (L1 – L4, Table V) and at the total hip 
(Table VI). Volunteers were offered full body composition analysis (optional). If a full 
body scan was performed, it was conducted before the serial L1-L4 and total hip 
measurements. Repositioning entailed removal of the leg support block, sitting followed 
by standing, several paces of normal walking, and then complete repositioning of the 
volunteer. All scans contributing to the precision assessment were performed within two 















Subject 1st Scan 2nd Scan 3rd Scan SD SD2 
LSC 1 1.221 1.225 1.221 0.00231 0.00001 
LSC 2 1.532 1.522 1.524 0.00529 0.00003 
LSC 3 1.153 1.153 1.171 0.01039 0.00011 
LSC 4 1.118 1.122 1.103 0.01002 0.00010 
LSC 5 0.908 0.918 0.902 0.00808 0.00007 
LSC 6 1.217 1.217 1.219 0.00115 0.00000 
LSC 7 1.106 1.101 1.100 0.00321 0.00001 
LSC 8 0.979 0.970 0.971 0.00493 0.00002 
LSC 9 1.226 1.227 1.225 0.00100 0.00000 
LSC 10 1.182 1.187 1.166 0.01097 0.00012 
LSC 11 1.253 1.238 1.239 0.00839 0.00007 
LSC 12 1.433 1.435 1.436 0.00153 0.00000 
LSC 13 1.104 1.123 1.109 0.00985 0.00010 
LSC 14 1.104 1.098 1.08 0.01249 0.00016 





Table V. Serial mean lumbar spine bone density values (g/cm2) for L1 – L4 in 15 male 
subjects scanned in August 2015 with repositioning between scans. SD = standard 






Step 1 involved simulating the distribution of T under the null hypothesis (H0). 
First, population parameters for μ (population mean), σ (population standard deviation), 
and ρ (correlation) were set. Next, a covariance matrix for each group (exposure and 
Subject 1st Scan 2nd Scan 3rd Scan SD SD2 
LSC 16 1.160 1.158 1.149 0.005859 0.000034 
LSC 17 1.195 1.204 1.192 0.006245 0.000039 
LSC 18 1.002 1.008 0.998 0.005033 0.000025 
LSC 19 0.955 0.956 0.940 0.008963 0.000080 
LSC 20 1.093 1.102 1.090 0.006245 0.000039 
LSC 21 1.023 1.015 1.022 0.004359 0.000019 
LSC 22 1.236 1.201 1.234 0.019655 0.000386 
LSC 23 0.987 0.990 1.001 0.007371 0.000054 
LSC 24 1.136 1.152 1.144 0.008 0.000064 
LSC 25 1.118 1.121 1.110 0.005686 0.000032 
LSC 26 1.268 1.267 1.271 0.002082 0.000004 
LSC 27 0.886 0.890 0.898 0.00611 0.000037 
LSC 28 0.998 1.001 0.995 0.003 0.000009 
LSC 29 1.100 1.097 1.107 0.005132 0.000026 





Table VI. Serial mean femoral neck bone density values (g/cm2) for the total hip in 15 
male subjects scanned July – September 2017 with repositioning between scans. SD = 
standard deviation; n = 15; RMSD = root mean square deviation, or, precision error.  
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control) was established. We are not able to make the assumption that the two variables 
being measured, Xbefore and Xafter, or Ybefore and Yafter, are independent. Therefore, 
simulation occurred for various sample sizes with 10,000 iterations of a multivariate, 
normal variable random sampling method. Average change and standard deviation in 
bone mineral density for exposure and control were calculated. α was set to 0.05 and 
distributions of test statistics were visually inspected through histogram. The 
programming code was developed and executed in R: a language and environment for 
statistical computing (65) and is provided as [Appendix 10]. 
Step 2 involved simulating the distribution T under Ha. μ was set to the 
population mean for all time points except for a 3% reduction in the exposure group. σ 
was set to be the same for both groups at all time points. ρ was set to be equal to ρ as for 
H0. The same covariance matrix was used for each group. Simulation also occurred with 
10,000 iterations of a multivariate, normal variable random sampling method. Average 
change and standard deviation were calculated. α was set to 0.05 and data were visually 
inspected through histogram. The programming code was developed and executed in R 
(65) and is provided as Appendix 10. 
Step 3 involved determining the critical value. In R, the quantile function was 
used to derive the critical value where the probability of the test statistic is greater than 
the critical value under H0. This value is equal to 1 – α. 
Step 4 involved computing power. In R, the power was computed by adding the 
values of the test statistic under Ha where this value was greater than the critical value. 
This sum was then divided by the number of simulated iterations.  
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Power simulations were conducted for a two measurement design: a baseline 
assessment of BMD and an assessment after one year of treatment (apheresis) or control 
(no apheresis). Mean and standard deviation of lumbar spine BMD were calculated from 
NHANES III as above and a 3% decline in BMD in the exposure group was selected as 
the primary outcome. Using this approach, power was calculated for various sample sizes 
and ρ = 0.1, 0.5, 0.9, 0.925, and 0.95. Because healthy men comprising this cohort have 
no change in BMD over a one year period on average (Looker, Melton et al. 2010), it was 
assumed that there would be a high degree of correlation between baseline and follow-up 
assessments (e.g. ρ = 0.99). The primary sources of variation in this model would be the 
technologist’s LSC and the variance of change in BMD for the exposure group. 
Attrition and Randomization 
 
Studies in blood donor populations with very similar interventions demonstrate 
highly varied degrees of attrition (e.g. (66, 67)). In the present study, all enrolled donors 
were recruited from a pool of donors willing to undergo high frequency apheresis. 
Nevertheless, it was expected that donors randomized to continue with apheresis as 
planned would demonstrate a higher rate of attrition relative to those randomized to 
forgoing apheresis for the one year follow-up period. To preserve this study’s analytic 
sample size, unequal attrition estimates were used to compute required enrollment sample 
sizes. 
In conclusion, an estimated 80% power was achieved with approximately 20 
subjects analyzed as treatment and 15 analyzed as controls. It was expected that donors 
randomized to apheresis would be more likely to undergo attrition. If one in five donors 
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randomized to treatment dropped out of the study (i.e. 20% attrition), then the probability 
of preserving the desired analytic sample size in this group was approximately 91% when 
28 donors are enrolled. The probability of preserving the desired analytic sample size in 
the control group, estimated to experience 5% attrition, was approximately 95% when 17 
donors were enrolled. Total enrollment cohort size in this scenario was n = 45 (28 + 17 = 
45). With approximately two thirds of the randomized cohort being assigned to treatment 
(62%), a 2:1 randomization was used. A projected subject workflow with numbers is 




Figure V. Projected subject workflow for ALTRUYST study showing effects of 
anticipated subject attrition rates and preservation of analytic sample size.  
 
Human Subjects Considerations 
 
This study was submitted to local Institutional Review Board (IRB) review prior 
to any human subjects participation. Informed consent was required due to radiation 
Assessed for Eligibility (n = 80)
Enrolled (n = 47)
CONTROL (n = 17)
Excluded (n = 3)
• BMD <-2.0 (n = 2)
• BMD > 2.0 (n = 1)
APHERESIS  (n = 27)
Lost to Follow-Up (n = 2)
Did not Comply (n = 5)
ANALYZED (n = 15) ANALYZED (n = 20)
Lost to Follow-Up (n = 2)
Did not Comply (n = 0)
Not Enrolled (n = 33) 
• risk factor (n = 5)
• unwilling to donate (n = 28)
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exposure associated with DXA and the randomized study design. There was no direct 
benefit to subjects who participated in this study other than remuneration for each DXA 
visit and study compliance, and, full body composition reports from DXA after study 
completion. If a participant was eligible based on the screening questionnaire, then there 
was a minimum of one suite of DXA scans performed at baseline. For participants who 
completed the study, a total of two suites of DXA scans were performed (one at baseline 
and one at follow-up). Each completed DXA assessment resulted in payment of $50 to 
the participant to remunerate costs associated with time and travel. Total remuneration 
for two suites of DXA scans was $100. In addition, participants who complied with the 
protocol intervention into which they were randomized (20 – 26 apheresis procedures, or 
no apheresis procedures during the follow-up) received additional compensation at the 
end of the study (equal to $100 or $250). The most an individual participant received as 
part of their participation in this study was $200 or $350, based on randomization and 
compliance. There was no remuneration granted to participants for any blood donation 
activities – these were all voluntary donations per FDA guidance. 
Women were not included in this study due to a high degree of variability in bone 
density both across age strata and over the life course (Looker, Melton et al. 2010). 
Because all participants were male, there was no need to assess child-bearing status 
before DXA in this cohort. The inclusion of racial minorities was not precluded; 
however, powering the study to detect between-race interactions was untenable based on 






Potential risks for participation in this study were associated with risks of 
venipuncture, exposure to radiation from DXA, and loss of confidentiality. Risks of 
venipuncture were the same as those for routine apheresis and whole blood donation 
which eligible subjects regularly accept. These risks were presented to volunteer blood 
donors at the time of every donation. This risk was considered minimal and was 
discussed in the informed consent document signed by all participants.  
Pencil beam BMD scanners employ a narrow (2-3 mm) x-ray beam with a single 
detector, while fan beam scanners use broader, fan shaped beams. The original version 
utilizes an array of multiple detectors in a single pass while the newer, narrow angle fan 
beam scanners have a smaller detector array and perform multiple, overlapping passes 
(68). Overall, fan beam scanners offer shorter scan times, better resolution, and slightly 
higher radiation doses than pencil beam scanners. DXA measurement was performed 
using fan beam scanners exclusively in this study. 
Although DXA conveys a relatively low radiation dose to the patient, the areas 
irradiated include sensitive organs such as the bone marrow, and in some instances, 
reproductive organs. Radiation dose is contingent upon the method and mode of delivery 
and the significance of the exposure depends upon the body part irradiated. The 
Radiological Society of North America (69) provides a comparison of radiation exposure 
from various procedures to natural environmental exposure. A typical whole body DXA 
scan is equivalent to three hours of natural background radiation. Overall, results show 
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that DXA is a low dose examination compared to other ionizing radiation procedures 
such as standard radiographs (70). Radiation exposure data are summarized in Table VII. 
 




Mammogram (70) 450 
Air Flight JFK to ORD 
(71) 390 
Chest X-Ray (70, 72) 100 
Daily Natural Exposure 
(70) 8 
Lumbar Spine DXA (73, 
74) 0.7 
Femoral Neck DXA (73, 
74) 0.7 
Whole Body DXA (72, 74) 3 
All 5 DXA Scans 5.8 
Table VII. Effective radiation dose for select natural 
exposures and exposures associated with dual energy 
x-ray absorptiometry (DXA) bone scans. 
 
Protection Against Study Risks 
 
While the radiation dose is low, there still may be concern with reproductive 
organ exposure. Any attempt at shielding has the potential to compromise scan results. 
Reproductive organ exposure to scattered radiation during the lumbar spine scan does 
occur, and exposure during hip scans is dependent on the size of the scan field (75). 
Although DXA scans deliver low radiation doses to patients compared to general-purpose 
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radiographic systems, technical competency is necessary to minimize unnecessary 
exposure and to produce accurate results. Improper patient positioning may result in 
unintended and unnecessary exposure to the patient as well as staff. The scan operator 
was therefore appropriately trained to perform scans safely, accurately, and reliably. The 
DXA facility performed quality control and precision testing to ensure accuracy and 
reproducibility of results (76). 
Staff persons involved in this project had extensive experience implementing 
clinical studies where confidential information is collected, stored, and utilized for 
research purposes. All original documentation were assembled in donor records 
maintained in secure locations at BloodCenter of Wisconsin and Marquette University 
facilities. Information on enrolled donors were identified by a unique, anonymized 
subject ID for the purposes of anonymity and laboratory testing. DXA measurement data 
remained in a secure-access room, on the access-restricted hard drive, at Marquette 
University or in the paper-based chart assembled at BloodCenter of Wisconsin. The only 
people with access to identifiable information in this study were CITI certified and listed 
as personnel on the IRB-approved protocol.  
Due to the limited interventional nature of this study (randomization and DXA) 
reporting requirements were limited to abnormal BMD discovered through DXA, losses 
of confidentiality, and adverse outcomes associated with venipuncture. All abnormal 
DXA results from this study [BMD Z-score <(-2.0) or >(2.0)] were reviewed by this 
study’s Medical Monitor. The recommendation to seek personal medical attention in the 
form of an IRB-approved letter was provided to subjects. These reports were generated 
on behalf of the Medical Monitor, shared with all study personnel, and reported to the 
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IRB as required. Adverse events associated with venipuncture were addressed per local 
protocol and reported to the IRB as required. 
This study’s Medical Monitor was an endocrinology-trained physician 
experienced in the diagnosis and treatment of patients with osteoporosis. Dr. Robert D. 
Blank, Chief of Endocrinology, Metabolism, and Clinical Nutrition at the Medical 
College of Wisconsin served as the Medical Monitor. This physician reviewed all 
abnormal DXA reports and adjudicated adverse findings as needed. Specifically, any 
BMD Z-score ≤(-1.9) or ≥(1.9), as determined by the DXA technologist were forwarded 
for review by the Medical Monitor. It is likely that upon notification of abnormal BMD, 
subjects would be evaluated, and possibly treated, for a bone or metabolism-related 
disease by their physician, thus affecting follow-up BMD measurements and confounding 
study results. Therefore, all subjects were asked as part of the risk assessment survey 
whether or not they are currently or have ever taken medications that are used in the 
treatment of low BMD. These data were used first to screen for eligibility and later upon 
data analysis. All subjects were given the results of their DXA results upon request, but 
only after completing their participation in the study to help mitigate potential 




The distributions of continuous and ordinal variables at baseline were compared 
using the t-test statistic and Fisher’s exact test, respectively. The primary outcome was 
defined a priori as change in lumbar spine BMD and the secondary outcome was change 
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in total hip BMD. The intention to treat analysis included all subjects who completed 
follow-up. A compliance analysis was also performed that included only those subjects 
who complied with the criteria of their randomization. Multivariable logistic regression 
was performed as an exploratory analysis using the questionnaire, laboratory, baseline 
BMD data, and, treatment arm as predictors of change in bone density exceeding the 
LSC. Bilirubin, alkaline phosphatase, and anion gap were log transformed to achieve 
normal distributions. Automated stepwise backwards elimination was subsequently 
performed to identify significant predictors of both positive and negative response. The 
programming code was developed and executed in R: a language and environment for 
statistical computing (65) and is provided as [Appendix 11]. 
TIMELINE 
The projected timeline for the ALTRUYST trial is presented in Table VIII.  
Activity Period 
Power Computation Spring 2015 
DXA Precision Assessment Summer 2015 
Finalize Proposal Fall 2015 
Clinical Trials.gov Registration Winter 2015 
IRB Submission Spring 2016 
Enroll Subjects Summer 2016 
Enroll Subjects & Follow-Up Fall 2016 
Follow-Up Spring 2017 
Final Visits Summer 2017 
Final Visits & Analysis & Publication Fall 2017 
Table VIII. ALTRUYST project timeline. 
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CHAPTER FOUR: ALTRUYST Results 
 
Human Subjects Approvals and Enrollment 
 
 BloodCenter of Wisconsin Quality Support Services supported the application for 
a determination that the proposed study remuneration plan was compliant with 21 CFR 
606.121(c)(8)(v) and local Compliance Guide 230.150 in February, 2016. The Blood and 
Tissue Compliance Branch (BTCB) at the US Food and Drug Administration (FDA) 
acknowledged that these requirements had been met and that the proposed donor 
incentive did not constitute monetary payment (Appendix 8) allowing labeling and 
transfusion of derived component blood products as “Volunteer Blood Donor”. 
Thereafter, the study team sought ceded IRB approval from the Marquette University 
Institutional Review Board (IRB). The Inter-Institutional Liaison for Human Research 
Protections approved the request in February, 2016 (Appendix 12). The study was then 
submitted to the Medical College of Wisconsin (MCW) IRB for approval. The 
Department of Physiology at MCW provided an attestation that the project had scientific 
merit, used procedures consistent with sound research design, and was likely to yield the 
expected knowledge; and that the proposal was a complete and coherent one on April 5, 
2016 (Appendix 12). Radiation verification and approval from the Radiation Safety 
Office at MCW was received on April 28, 2016 (Appendix 13). The study was reviewed 
by Institutional Review Board #3 on April 26, 2016. The Committee determined that the 
study met all criteria under 21 CFR 56.111 and provided an approval notice (Appendix 
14). IRB-approved screening methods commenced and the first subject was enrolled per 
protocol on May 18, 2016 and the final subject was enrolled on January 28, 2017. Figure 
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VI shows 100%, 75%, and 50% of enrollment goals with actual enrollment numbers 
(black line) and the number of eligible enrollees (dashed line) superimposed over the 
projected 100% (green), 75% (yellow) and 50% (red) cumulative accrual numbers.  
 
 
Figure VI. Cumulative enrollment chart showing 100%, 75%, and 50% 
enrollment goals with actual and eligible numbers superimposed. 
 
Enrollment and Analytic Samples 
 
Among 120 volunteer blood donors assessed for eligibility, 58 enrolled in the 
study (Figure VII). Seven enrollees were subsequently excluded for having a bone 
density Z score <-2.0 or > 2.0 at enrollment. Three additional subjects were excluded for 
having previously undergone apheresis more than five times and one subject was 
excluded for weighing more than 300 pounds. Ultimately, 32 subjects were randomized 
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to apheresis and 15 to the control arm. Approximately 20% of subjects from the apheresis 
arm were not available at follow-up: two subjects voluntarily withdrew from the study 
(6%) and four subjects were lost to follow-up (11%). All subjects in the control arm were 
available at follow-up. 
 
 
Figure VII. Enrollment schematic showing recruitment, enrollment, ineligibility, and 
losses to follow-up for the ALTRUYST trial. ITT = Intention to Treat 
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Baseline Demographics, Laboratory Test Results, and Donation History 
 
The distributions of baseline characteristics are provided in Figure VIII. A 
peripheral blood sample was not available for four participants. Bilirubin, alkaline 
phosphatase, and anion gap were log transformed for all donors to achieve normal 
distributions (Figure IX). Male, adult testosterone concentrations were below the lower 
normal range cutoff in three donors: two in the treatment arm and one in the control arm. 
Mean age at enrollment was 43.8 years (SD = 13.5) with one donor (2%) reporting 
African American race and another (2%) reporting Hispanic ethnicity (Table IX). Mean 
height (p=0.89), weight (p=0.25), and body mass index (BMI) (p=0.38) were no different 
between study arms. Baseline laboratory parameters were similar between groups 
(p=0.14-0.97), as were the number of previous whole blood (median = 5, p=0.73) and 
apheresis (median = 3, p=0.49) donations. Though lumbar spine bone density was not 
different between study arms (p=0.26), bone density at the total hip was, on average, 
0.107 g/cm2 higher among those donors randomized to the apheresis arm (p=0.03) (Table 
IX).  The lower limit of the reference range for testosterone is 300ng/dL and three 
individuals were below that value at enrollment. The only individual among these three 
who experienced clinically meaningful change in BMD was a 25 year old male in the 
control group who experienced a 4.3% decline in total hip BMD and 2.2% decline at the 
L-spine. The only other laboratory value out of the normal reference range was anion 












Figure IX. Effect of log-transforming anion gap, alkaline phosphatase, and bilirubin on 




Table IX. Descriptive characteristics of ALTRUYST blood donors at enrollment. 
 Apheresis No Apheresis Total p 
n 26 15 41 - 
DEMOGRAPHICS 
Age (mean, SD) 42.6 (13.1) 45.9 (14.3) 43.8 (13.5) 0.46 
Caucasian (n, %) 25 (96%) 15 (100%) 44 (98%) - 
Latino/Hispanic (n, %) 1 (4%) 0 (0%) 1 (2%) - 
ANTHROPOMETRICS1 
Height (inches) 70.4 (2.4) 70.2 (3.2) 70.3 (2.7) 0.89 
Weight (pounds) 203.2 (32.2) 191.7 (29.0) 199.0 (31.2) 0.25 
Body Composition (% body fat) 28.9 (4.7) 27.5 (5.0) 28.4 (4.8) 0.38 
LABORATORY DATA1 
Serum Sodium (mmol/L) 143 (2.3) 142 (2.1) 143 (2.3) 0.24 
Serum Potassium (mmol/L) 4.5 (0.3) 4.7 (0.3) 4.6 (0.3) 0.38 
Serum Chloride (mmol/L) 101 (1.9) 100 (3.0) 101 (2.3) 0.37 
Serum Carbon Dioxide (mmol/L) 22 (1.5) 21 (1.5) 22 (1.5) 0.19 
Anion Gap (mmol/L) 20 (2.2) 20 (1.8) 20 (2.0) 0.34 
Serum Urea Nitrogen (mg/dL) 16 (3.7) 15 (5.3) 15 (4.2) 0.80 
Serum Creatinine (mg/dL) 1.00 (0.14) 0.99 (0.15) 1.00 (0.14) 0.83 
Serum Glucose (mg/dL) 97 (16) 101 (25) 98 (19) 0.66 
Alkaline Phosphatase (U/L) 67 (15) 75 (22) 70 (18) 0.33 
Aspartate Aminotransferase (U/L) 26 (8) 27 (4) 26 (7) 0.53 
Alanine Aminotransferase (U/L) 25 (12) 25 (7) 25 (10) 0.97 
Serum Calcium (mg/dL) 9.7 (0.4) 9.7 (0.5) 9.7 (0.4) 0.93 
Serum Inorganic Phosphorous (mg/dL) 3.3 (0.5) 3.5 (0.4) 3.4 (0.5) 0.14 
Serum Total Protein (g/dL) 7.2 (0.4) 7.4 (0.5) 7.3 (0.5) 0.39 
Serum Albumin (g/dL) 4.6 (0.3) 4.7 (0.3) 4.6 (0.3) 0.49 
Serum Total Bilirubin (mg/dL) 0.6 (0.4) 0.6 (0.3) 0.6 (0.3) 0.95 
Adult Male Testosterone (ng/dL) 520 (198) 515 (202) 518 (196) 0.94 
PREVIOUS BLOOD DONATIONS2 
Whole Blood (n) 6 4 5 0.73 
Apheresis (n) 3 3 3 0.49 
BONE DENSITY1 
Lumbar Spine (g/cm2) 1.214 (0.130) 1.168 (0.120) 1.197 (0.127) 0.26 







Blood Donations During ALTRUYST 
 
 ALTRUYST donors made a total of 534 combined blood donations during the 
one year study period (Figure X). All 15 (100%) donors randomized to the control arm 
complied with the protocol (three made zero donations, Figure X), whereas five (19%) 
apheresis donors did not achieve a minimum of 20 apheresis donations (Figure X). The 
most common apheresis donation type was a double platelet donation with mean interval 
between donations of 17.8 days (Table X). Donors in the apheresis arm experienced a 
median of 20 apheresis blood donations during the one year study period with the amount 
of citrate exposure by donation type ranging from 164mL – 657mL (Table X). The 
duration of each donation ranged from just under 30 minutes to more than two hours in 
length. 
 
Table X. Apheresis collection and anticoagulant exposure characteristics for donors 
randomized to the treatment arm (high frequency apheresis) during the ALTRUYST 
trial.  
 Single Double Triple 
Collection 
Information 
Number of Platelet Apheresis 
Donations  110 320 62 
Concurrent Plasma Collection     n 
(%) 0 (0%) 4 (1%) 0 (0%) 








Mean (SD) Inter-Donation Interval 
(days) 17.8 (14.7) 
Anticoagulant 
Exposure 
Type of Anticoagulant ACD-A1 














Figure X. Cleveland dot plot of donations (solid dots, n = 543) and deferrals (open dots, 
n = 38) from donors during the ALTRUYST study. The top panel shows donors 
randomized to apheresis and the bottom panel shows donors randomized to no apheresis 
(i.e. whole blood only). Each donor is represented as a row with the number of successful 






Lumbar spine bone mineral density did not change among donors in the control 
arm after one year of participation (1.168 g/cm2 at enrollment, 1.170 g/cm2 at follow-up, 
mean change = -0.002 g/cm2, 95%CI [-0.020, 0.016], p=0.16), nor did it change among 
donors in the apheresis arm (1.214 g/ cm2 at enrollment, 1.213 g/cm2 at follow-up, mean 
change = 0.007 g/cm2, 95%CI [-0.005, 0.018], p=0.24) (Figure XI). Tests for differences 
in proportions of donors with change in BMD exceeding the least significant change 
(LSC) at the lumbar spine (0.00743 ±0.02058g/cm2) between the apheresis and control 
arms in either a positive [apheresis 13 (50%), control 5 (33%), p=0.84] or negative 
direction [apheresis 8 (31%), control 6 (40%)] were statistically non-significant (p=0.87) 
(Figure XII). Performing the analysis with only those donors who complied with the 
protocol (i.e. apheresis donors making ≥20 apheresis donations) did not meaningfully 
































Figure XI. Boxplot showing change in bone mineral density at 
the lumbar spine for control (left, n = 15, mean change=-0.002 
g/cm2, 95% CI [-0.020, 0.016], p=0.78) and apheresis (right, n 
= 26, mean change=0.007 g/cm2, CI [-0.005, 0.018], p=0.24) 
donors in the ALTRUYST trial. Diamonds indicate mean 
values; median change is represented as the central horizontal 
bar within the interquartile range box. The blue shaded region 




Figure XII. Proportion of subjects experiencing a decrease (left) (LS = lumbar spine, 
apheresis 8 (31%), control 6 (40%)) or increase (LS right, apheresis 13 (50%), control 5 
(33%)) in BMD exceeding the least significant change. Proportion of subjects 
experiencing a decrease (left) (TH = total hip, apheresis 11 (42%), control 3 (20%) or 
increase (LS right, apheresis 6 (23%), control 6 (40%)) in BMD exceeding the least 
significant change for LS and TH. Donors in the apheresis arm are in light blue and 




 Change in mean BMD at the total hip was not statistically significant for control 
donors (1.026 g/cm2 at enrollment, 1.028 g/cm2 at follow-up, mean change = 0.002 





















g/cm2 at follow-up, mean change = -0.004 g/cm2, CI [-0.10, 0.002], p=0.16) (Figure 
XIII). Proportional increases [apheresis 6 (23%), control 6 (40%), p=0.25] and decreases 
[apheresis 11 (42%), control 3 (20%)] were also not significantly different (p=0.15) at the 
total hip (LSC=0.00671±0.01859g/cm2) (Figure XII). Performing the analysis with only 
those donors who complied with the protocol (i.e. apheresis donors making ≥20 apheresis 






Mean femoral neck bone mineral density did not change among donors in the 
control arm after one year of participation (0.969 g/cm2 at enrollment, 0.969 g/cm2 at 
follow-up, mean change = 0.000 g/cm2, 95%CI [-0.009, 0.009], p=0.63), nor did it 
change among donors in the apheresis arm (1.094 g/cm2 at enrollment, 1.093 g/cm2 at 



























Figure XIII. Boxplot showing change in bone mineral density 
at the total hip for control (left, n = 15, mean change=0.002 
g/cm2, 95% CI [-0.006, 0.009], p=0.63) and apheresis (right, n 
= 26, mean change-=0.004 g/cm2, CI [-0.010, 0.002], p=0.16) 
donors in the ALTRUYST trial. Diamonds indicate mean 
values; median change is represented as the central horizontal 
bar within the box representing the interquartile range. The 




Mean trabecular bone score was 1.388 (SD = 0.098) in the control group at enrollment 
and did not significantly change over the one year study period (1.406 (SD = 0.112) at 
follow-up, mean change = -0.003, 95%CI [-0.024-0.019], p=0.79). Donors in the 
apheresis arm had a mean trabecular bone score at enrollment of 1.474 (SD = 0.105) and 
it did not change over the one year study period (1.475 (SD = 0.133) at follow-up, mean 
change = 0.001, 95%CI [-0.022, 0.024], p=0.92).  
 
Multivariable Logistic Regression 
 
 Multivariable logistic regression with change exceeding the LSC in both positive 
(gain in BMD) and negative (loss of BMD) directions using automated stepwise 
backwards elimination did not identify baseline covariates that were significantly 
associated with either outcome (Table XI). This was an exploratory analysis as the study 
was not powered to identify significant predictors. The regression took the general form: 
logit[pr(Y=1)] = β0 +  β1 (apheresis) +  β2 (age) +  β3 (risk factors=1) + β4 (risk 
factors=2) + β5 (risk factors=3) + β6 (risk factors=1) + β7 (family history=1) + β8 
(family history=2) + β9 (family history=3)+ β10 (health conditions=1) + β11 (health 
conditions=2) + β12 (medication use=1) + β13 (diet=3) + β14 (diet=4) + β15 (diet=5) 
+  β16 (diet=6) + β17 (diet=7) + β18 (medication use=2) + β19 (BMI) + β20 
(pre_(site)) + β21 (Na) + β22 (K) + β23 (Cl) + β24 (CO2) + β25 (anion gap) + β26 
(urea) + β27 (creatinine) + β28 (glucose) + β29 (alkaline phosphatase) + β30 (AST) + 




Table XI. Results of exploratory multivariable logistic regression analysis with change 
in bone mineral density as the outcome [coefficient (p value)]. 









Apheresis versus No 
Apheresis 0.49 (0.04) 1.64 (0.36) 0.48 (0.19) -0.80 (0.53) 
Age -0.03 (0.03) 0.00 (0.92) 0.04 (0.09) 0.02 (0.53) 
Risk Factors = 1 -0.54 (0.06) -0.25 (0.79) -0.25 (0.38) 0.06 (0.94) 
Risk Factors = 2 -0.15 (0.22) 1.28 (0.54) -0.23 (0.44) -1.17 (0.52) 
Risk Factors = 3 -0.65 (0.09) 0.33 (0.87) -0.83 (0.24) -0.17 (0.92) 
Risk Factors = 4 -2.70 (0.03) 2.57 (0.54) 2.79 (0.11) -2.59 (0.49) 
Family Risk Factors = 1 -0.27 (0.17) 0.70 (0.69) -0.95 (0.17) -1.78 (0.36) 
Family Risk Factors = 2 -0.96 (0.04) 0.33 (0.81) -0.11 (0.71) -1.51 (0.34) 
Family Risk Factors = 3 -1.09 (0.07) 1.56 (0.64) 0.18 (0.76) -4.15 (0.30) 
Health Conditions = 1 1.13 (0.03) 0.86 (0.58) 0.06 (0.83) -0.12 (0.92) 
Health Conditions = 2 2.99 (0.05) -0.52 (0.92) 1.78 (0.26) 3.30 (0.51) 
Medication Use = 1 -0.53 (0.09) -0.76 (0.64) -0.95 (0.16) 0.02 (0.99) 
Diet = 3 0.31 (0.11) 0.71 (0.65) -0.04 (0.87) -0.05 (0.97) 
Diet = 4 -0.11 (0.36) 0.57 (0.75) 0.55 (0.27) -0.09 (0.95) 
Diet = 5 0.91 (0.04) -0.29 (0.81) -1.69 (0.08) -0.47 (0.67) 
Diet = 6 1.40 (0.03) -0.85 (0.60) -1.16 (0.14) 1.45 (0.39) 
Diet = 7 5.05 (0.02) -0.97 (0.77) -1.05 (0.31) 2.58 (0.45) 
Body Mass Index 0.04 (0.07) -0.06 (0.61) 0.01 (0.75) 0.11 (0.38) 
Baseline BMD 4.54 (0.03) -4.69 (0.50) -5.65 (0.08) 4.21 (0.48) 
Serum Sodium -0.11 (0.11) -0.62 (0.41) -0.30 (0.14) 0.44 (0.47) 
Serum Potassium 0.60 (0.08) -0.59 (0.75) -2.16 (0.08) -0.35 (0.82) 
Serum Chloride -0.15 (0.10) 0.54 (0.46) 0.11 (0.43) -0.63 (0.37) 
Serum Carbon Dioxide -0.12 (0.07) 0.06 (0.87) 0.29 (0.11) 0.10 (0.77) 
Serum Urea Nitrogen 0.15 (0.02) -0.05 (0.59) -0.12 (0.09) 0.05 (0.55) 
Serum Creatinine -4.15 (0.03) 4.25 (0.60) 2.44 (0.17) -3.84 (0.58) 
Serum Glucose 0.00 (0.40) 0.02 (0.50) -0.02 (0.14) -0.05 (0.25) 
Alkaline Phosphatase -0.01 (0.13) 0.02 (0.50) 0.02 (0.18) 0.00 (0.98) 
Aspartate Aminotransferase 0.01 (0.18) 0.08 (0.53) 0.03 (0.23) -0.03 (0.74) 
Alanine Aminotransferase -0.06 (0.03) 0.04 (0.65) 0.08 (0.09) -0.04 (0.60) 
Serum Calcium -0.51 (0.10) 0.56 (0.83) 0.37 (0.40) -2.51 (0.39) 
Serum Inorganic 
Phosphorous -0.02 (0.67) 0.56 (0.63) -0.40 (0.19) -0.39 (0.69) 
Serum Total Protein -0.24 (0.28) -0.58 (0.75) -2.24 (0.11) 0.23 (0.88) 
Serum Albumin -0.51 (0.18) 0.68 (0.83) 4.42 (0.07) 1.79 (0.55) 
Serum Total Bilirubin -0.15 (0.22) 1.06 (0.62) -1.55 (0.08) -2.09 (0.36) 





Dual-Energy X-ray Absorptiometry Calibration 
 
 Appendix 15 shows the quality assurance data for the period of image acquisition 
(May 1, 2016 – February 1, 2018). During this period, 597 phantom scans were 
performed per protocol. A phantom scan was performed within the 48 hour period 
preceding every ALTRUYST scan. Density of the phantom is 1.497, 0.995, and 0.497 
g/cm2 at the high, medium, and low bands, respectively. The percent coefficient of 
variation was 0.3%, 0.6%, and 1.3% for high, medium, and low BMD regions during the 
period of scan acquisition, respectively. Overall BMD precision was 0.24% (Appendix 
15). The machine was not moved during the project period, and, all routine service and 




ALTRUYST was a prospective, longitudinal, randomized controlled trial 
evaluating the role of high frequency apheresis blood donation on change in BMD. There 
were no significant alterations to BMD at the lumbar spine or total hip. Therefore, the 
null hypothesis that high frequency apheresis blood donation does not cause significant 
declines in BMD after a one year follow-up period cannot be rejected. Analyses of 
secondary outcome measures indicate that there were no significant changes in mean 
femoral neck BMD, nor trabecular bone scores. Multivariable logistic regression was not 
able to identify significant predictors of either positive or negative change at any site 
measured due to potential lack of statistical power. An analysis of those apheresis donors 




CHAPTER FIVE: ALTRUYST Discussion 
 
ALTRUYST was a prospective, longitudinal, randomized controlled trial 
evaluating the role of high frequency platelet apheresis blood donation on change in 
BMD in males and found no significant alterations to BMD at the lumbar spine or total 
hip. Previous studies demonstrated a higher prevalence of low BMD among apheresis 
donors when compared to non-blood donors (11) or whole blood donor controls, (12) 
independent of donor gender or age. One study reported no difference among apheresis 
and whole blood donors (13). These conflicting results likely stem from the cross-
sectional designs employed in these previous investigations. Important determinants of 
BMD include genetic (77) and behavioral factors (78) that have been integrated into 
previous study designs to varying degrees. Using an individual blood donor as their own 
control represents a key feature of ALTRUYST supporting the conclusion that very high 
frequency platelet apheresis, and concomitant exposure to large doses of citrate AC, over 
a one year period do not induce changes in BMD. Furthermore, BMD of a control group 
randomly assigned to no apheresis remained unchanged during the study period, 
consistent with large studies of the male US population 18-65 years of age (79).  
In the absence of fracture, low BMD is the single best predictor of fracture risk 
(64) and the corresponding association is exponential (80). Analysis of more than 
140,000 Swedish blood donors over a 23 year period demonstrated no association 
between the risk of fracture and, mostly (94-98%), plasma apheresis (56). Plasmapheresis 
collections expose donors to a fraction of the AC that platelet apheresis donors receive 
(23) and high frequency platelet apheresis donors were not present in the SCANDAT2 
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analysis. Donors in the ALTRUYST trial almost exclusively donated platelets by 
apheresis (<1% of donations involved concurrent plasma collections) and received an 
average of between 300mL (single platelet apheresis) and 500mL (triple collections) of 
AC per procedure with an average of 17 days between exposures. Most ALTRUYST 
donors in the apheresis arm (21/26, 81%) achieved 20 or more apheresis donations during 
the one year study period. No donors in the ALTRUYST study experienced fracture 
during the follow-up period. Risk for low trauma fractures among otherwise healthy 
males 18-65 years of age is essentially zero,(81, 82) and, ALTRUYST was not powered 
using significant change in fracture risk as an outcome. Nevertheless, the finding that the 
upper limit of citrate AC exposure, both in terms of dose and frequency, failed to produce 
significant alterations to BMD among these donors indicates that current apheresis 
collection guidelines are adequate in protecting the bone health of the volunteer blood 
donor population and do not likely alter fracture risk in this donor population.  
Dual-energy x-ray absorptiometry (DXA) is the industry standard for assessing 
bone mineral density and has many strengths relative to other BMD technologies. Access 
to large reference databases, including the National Health and Nutrition Examination 
Survey, permitted estimation of population mean and standard deviation bone mineral 
density values, specifically for the age- and gender-eligible group, before enrolling 
subjects in ALTRUYST. This feature of DXA allowed for robust modeling of power and 
sample size to occur in advance of the study itself. DXA is also the most accurate way of 
measuring BMD. The fact that not all insurance providers cover BMD assessment using 
DXA does not impact the decision to employ this as the primary outcome as all scans 
were provided to subjects free of charge. However, the acquisition of dual photon 
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absorptiometry (DPA) images requires significantly more time, which may have made 
recruitment for ALTRUYST challenging. Quantitative computed tomography (CT) 
provides three-dimensional images at the lumbar spine and has superior ability to 
measure changes in trabecular bone earlier than DXA (83). A lack of large reference 
databases for quantitative CT, inferior precision, and effective radiation doses several 
orders of magnitude higher than DXA are fundamental drawbacks to using this 
technology. Ultimately, the ability for DXA to accurately measure areal BMD at the 
lumbar spine and total hip, with minimal costs to subjects in terms of time and comfort, 
enriched the overall feasibility of performing this clinical trial.  
ALTRUYST was 80% powered to detect a 3% change in bone mineral density 
over the one year study period. Though mean bone mineral density was higher in the 
ALTRUYST cohort relative to a gender- and age-matched sample of the US population, 
this is expected due to a well known “healthy donor effect” where volunteer blood donors 
consistently present with health indices superior to population norms (84). Furthermore, 
the variability about the measure of central tendency among ALTRUYST donors 
indicates that individuals within the cohort were not contributing any outlier effects that 
could bias our assessment of the study’s outcomes. This is, in part, due to the fact that 
ALTRUYST deliberately excluded individuals with BMD that fell outside of a 95% 
population-based estimate of mean BMD (i.e. ±2 standard deviations of Z-score). Seven 
individuals enrolled in ALTRUYST met this criterion and required exclusion per 
protocol. The higher than anticipated prevalence of abnormal BMD in the enrolled cohort 
cannot be explained, other than the possibility that such an observation was spurious. The 
exceedingly low dose of radiation these individuals experienced represents another aspect 
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of DXA that illustrates its superiority in assessing BMD in clinical studies. Other 
limitations of DXA are primarily related to potential sources of error, including 
differences observed among the three commercial manufacturers, differences in edge 
detection softwares, the need for rigorous quality control across systems when multiple 
sites are involved due to differences in x-ray tube or detector functionality, technologist-
related sources of error, and various sources of shift and drift in these finely tuned and 
calibrated systems. ALTRUYST was a single-center study that used one GE DXA 
instrument, one technologist performed all study scans, and shift and drift were quantified 
throughout the period of measurement. These design features represent a strength in the 
ALTRUYST study and illustrate the much larger sample sizes that would be required to 
perform such a study at multiple centers. 
BMD over the life course is largely influenced by heritability. Individual 
aberrancies in BMD were accounted for using the exclusion criterion for BMD exceeding 
two standard deviations of an age- and gender-matched mean value at enrollment. Family 
history of fractures was solicited from participants at enrollment through the use of the 
questionnaire. Any familial predisposition to disease of bone and mineral metabolism 
were coded as an ordinal variable, where the mean value was one and the median value 
was also one, were added into the multivariable logistic regression. This predictor did not 
achieve significance for changes either in the positive or negative direction. Further, the 
randomized nature of this study ensured that the likelihood of being assigned to either 
group was equivalent. Nevertheless, confounding could occur if subjects experienced 
changes to other important determinants of BMD including physical activity, diet, and 
medication use. In addition to excluding subjects with known diseases of bone and 
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mineral metabolism, subjects were deliberately excluded if they were taking medications 
known to impact BMD. Upon follow-up assessment, no changes in medication were 
noted meaning that any confounding from medication use was absent. Physical activity 
did not differ between the two randomized groups, and, changes in physical activity 
sufficient to invoke changes in BMD over the one year interval did not occur. The self-
report questionnaire was administered by the investigative team to avoid any non-
response bias. These design features and observations indicate that the findings of 
ALTRUYST are extremely unlikely to have known confounding that could have 
impacted the results of the study and though the potential for residual, unmeasured 
confounding can never be completely eliminated, the complete lack of any significant 
change in any outcome measured suggests that any such effect was minimal if present. 
In addition to progressive declines in bone density, microarchitectural 
deterioration of bone is a fundamental part of the definition of diseases of reduced BMD 
(85, 86). Among these microarchitectural features are the number of trabeculae, 
separation between trabeculae, and the density of connections between trabeculae. 
Changes in these three dimensional features are associated with increasing bone fragility 
and susceptibility to fracture, (14, 87) even when bone density is the same between two 
samples. The trabecular bone score (TBS) is an analytic tool that quantifies the extent of 
between-pixel differences in x-ray attenuation from dual-energy x-ray absorptiometry 
images approximating microarchitectural features of bone. In contrast to alternative 
techniques for examining bone microarchitecture, obtaining TBS is non-invasive and 
uses standard dual-energy x-ray absorptiometry images of the lumbar spine, making it 
ideally suited to quantify microarchitectural changes in healthy volunteers. TBS did not 
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change among ALTRUYST donors in the apheresis arm, or among donors in the control 
arm. This finding is consistent with previous research showing that the magnitude of 
change in TBS is less than that of areal BMD in the spine.(88-90) Findings from 
ALTRUYST are also consistent with the observation that TBS remains relatively 
unchanged before the age of 45 years (91). Future research examining the potential 
anabolic effect of repeated apheresis blood donation among aging women would be an 
appropriate setting to explore changes in TBS in addition to BMD. 
Apheresis induces the secretion of parathyroid hormone (26, 38, 39) and three 
cascading physiologic processes ensue: increased calcium reabsorption in the distal 
convoluted tubule, increased intestinal calcium absorption, and increased bone resorption. 
Data from ALTRUYST indicate that any increase in bone resorption among apheresis 
donors did not alter bone density more than what was defined as clinically meaningful a 
priori. Surprisingly, apheresis-induced surges in parathyroid hormone produce renal 
calcium loss (35, 92). Absorptive hypercalciuria is associated with increased urinary 
calcium loss resulting from increased absorption of calcium in the intestine. The elevated 
absorption of calcium can be controlled with ingestion of cellulose phosphate that binds 
free calcium in the gut (93). Hypercalciuria is also one of the clinical manifestations of 
Bartter’s syndrome where genetic mutations in renal sodium-potassium-chloride co-
transporters serve as the etiological foundation for this disease (94) and suggest genetic 
modifiers of mineral homeostasis could also contribute to the likelihood of an individual 
donor’s response to repeated apheresis. In all cases of hypercalciuria, the formation of 
calcium stones (nephrolithiasis) is an associated untoward health outcome. Therefore, the 
observation that apheresis donors experience hypercalciuria subsequent to donation 
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invokes the possibility that apheresis could meaningfully increase the risk of 
nephrolithiasis among donors. Because the formation of calcium stones is a health 
outcome with a relatively long latency, case-control studies could theoretically examine 
this possibility if medical records and blood donation records were linked. 
Disrupting the production of parathyroid hormone to circumvent the renal 
excretion of calcium in apheresis donors could theoretically be achieved by providing 
oral or intravenous calcium to supplant the biological stimulus for parathyroid hormone 
production (namely, reduced serum ionized calcium). Because citrate administration 
occurs at the point of venipuncture, any co-administration of calcium avoids interference 
with citrate’s role in providing anticoagulation in the extracorporeal circuit. However, 
urinary loss of calcium was not suppressed in a placebo-controlled study where oral 
calcium was provided to apheresis donors (31). Furthermore, prophylactic intravenous 
calcium fails to abrogate the urinary loss of calcium induced by apheresis (35). It is 
therefore likely that urinary calcium loss is an obligatory side effect of apheresis blood 
donation. Exogenous 1,25 di-hydroxy-vitamin D increases serum calcium through 
intestinal absorption and can indirectly modify the set point of parathyroid hormone (95). 
Exposure to citrate AC during apheresis blood donation results in surges of parathyroid 
hormone in apheresis blood donors that acutely suppresses serum ionized calcium 
concentrations. ALTRUYST deliberately recruited healthy volunteers, naïve to apheresis, 
and their laboratory test results at baseline were within expected ranges. Therefore, it is 
plausible that high frequency apheresis could have altered the set point of parathyroid 
hormone with repeated donation during the study. In addition to altering the set point of 
parathyroid hormone, studies among patients with vitamin D deficiency have indicated 
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that the kidneys can become more sensitive to parathyroid hormone over time (96). This 
observation invokes the complimentary possibility that the body copes with high 
frequency apheresis blood donation by altering the exchange of phosphate in the 
proximal convoluted tubule and calcium in the distal convoluted tubule of kidney 
nephrons. Serial serum samples were not obtained from ALTRUYST participants largely 
due to concerns around anticipated upper limits of allowable volume depletion in 
volunteer blood donors. The physiological mechanism that permits high frequency 
apheresis blood donation without alterations to bone mineral density is a provocative 
question and future studies would need to integrate design features that stimulate repeated 
surges in parathyroid hormone without losing participants to follow-up whose donation 
volumes are in excess of accepted standards. 
Secondary hyperparathyroidism is a clinical condition that results in sustained 
elevations in parathyroid hormone. Insufficient excretion of phosphate, an inability to 
produce 1,25 di-hydroxy vitamin D, vitamin D deficiency, and intestinal malabsorption 
are among the causes of secondary hyperparathyroidism and the clinical sequelae include 
decreased BMD. Because parathyroid hormone concentrations surge in the 60-90 minute 
interval when apheresis is being performed (11, 22, 38, 39), we hypothesized that 
frequent, repeated surges in parathyroid hormone from apheresis blood donation could 
reduce BMD through osteoclastic osteolysis. One clinical feature of secondary 
hyperparathyroidism is the enlargement of the glands themselves (parathyroid gland 
hyperplasia) that can be reversed with medication (97), illustrating the ability of the 
parathyroid glands to adapt to chronic stress. In contrast to secondary 
hyperparathyroidism where parathyroid hormone production is chronically increased, the 
81 
 
recovery of parathyroid hormone to pre-apheresis levels in donors after 120 minutes (11)  
may suggest that the stress of apheresis is insufficient to produce hyperplasia in the 
parathyroid glands in apheresis donors. Though high frequency apheresis blood donation 
does not induce changes in BMD, the possibility that morphological changes in donor 
parathyroid glands do not occur cannot be ruled out. 
Understanding how the stimulus for parathyroid hormone secretion is received by 
the parathyroid glands could provide another mode for mitigating the large surges in 
parathyroid hormone experienced by apheresis blood donors. The calcium-sensing 
receptor (CASR) is a membrane spanning protein that plays a central role in maintaining 
calcium homeostasis in the blood (37) making it an ideal candidate to consider in the 
context of personalized apheresis blood donation. Homozygous lack of function 
mutations in the CASR gene cause neonatal severe hyperparathyroidism, an autosomal 
dominant heritable disease that can be fatal if the parathyroid gland isn’t removed (98-
100). Heterozygous lack of function mutations in the CASR gene cause familial 
hypocalciuric hypercalcemia resulting in altered bone mineralization and increased 
incidence of kidney stones (101-103).  These clinically apparent diseases have led to the 
careful characterization of the CASR (e.g. (104)), including the assessment of CASR 
genotype on calcium. A meta-analysis by He and colleagues (105) found that one or two 
serine substitutions at locus 986 of CASR resulted in significantly higher total (0.028; 
0.012-0.045, P=0.001) and ionized calcium (0.016; 0.013-0.020, P<0.0001) as compared 
to subjects homozygous for alanine. Nevertheless, studies combining clinical outcomes, 
such as low bone density and kidney stones, with measurements of extracellular calcium 
were not able to consistently show detrimental effects of CASR mutations on these 
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measures [e.g. (106)] and it is unlikely that blood collecting agencies would genotype 
donor polymorphisms for CASR or other potential determinants of mineral homeostasis 
before permitting apheresis blood donation. Furthermore, results from ALTRUYST 
indicate that any such efforts would primarily target modest improvements in donor side 
effects to citrate exposure and not long term health outcomes.  
ALTRUYST deliberately studied male blood donors because they constitute the 
vast majority (approximately 80%) of the apheresis blood donor population at 
BloodCenter of Wisconsin, with 85% of higher frequency donors (defined as ≥15 
apheresis donations within a one year period) also male. Furthermore, the study recruited 
donors with no more than five lifetime apheresis donations so as to avoid any potential 
biological adaptation that may occur with repeated exposure to citrate AC.  Though we 
report no change in bone mineral density among men, aged 18-65 years, experiencing 
high frequency apheresis over a one year period, we are unable to extrapolate these 
findings to women of any age. There remains the possibility that high frequency 
apheresis affects women differently than men, particularly during the peri-menopausal 
period when changes in serum estrogen have been correlated with large fluctuations in 
BMD with supplemental estrogen improving bone-related health outcomes (107, 108). 
The scarcity of higher frequency female apheresis donors at the blood center studied 
indicate that any exploration of the impact of high frequency apheresis on BMD among 
women would require a multi-center design, and, careful consideration of how to 
concurrently mitigate the effects of iron deficiency associated with regular platelet 
apheresis blood donation (109) that disproportionately impact women (110). 
Furthermore, the high prevalence of low BMD among women, especially that increases 
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over the life course (111), indicates this would be an ideal group to evaluate the possible 
benefit of repeated alterations to PTH through apheresis (53, 112) that resemble those of 
synthetic PTH treatments for osteopenia/osteoporosis with demonstrable improvement in 
BMD (14).  
Before 1988, the US Food and Drug Administration allowed individual volunteer 
donors to make 12 apheresis platelet donations per year (9). Two studies presented in an 
AABB Advisory Committee comment made in 2006 (113) predate a policy change 
increasing the number of donations an individual volunteer donor can make to 24 
apheresis platelet donations per rolling 12 month period with no lifetime maximum (114).  
In one of these studies (6), 335 donors underwent platelet apheresis at frequent, but 
highly varied collection intervals. Initially, platelet count and yield declined to nadir 
between the seventh and ninth donation. However, a progressive rise in platelet count 
was observed over the course of repeated donations and recovery was achieved at the 
tenth donation for many donors despite continued collections. The safety of repeated 
collections was illustrated by the fact that at no time a donor exhibited a platelet count 
putting them at risk for acute bleeding (8), nor did any develop signs of persistent 
thrombocytopenia. A second study (8) is referenced in the Guidance where 105 platelet 
apheresis donors of various collection intensities (single, double, and triple product 
donors) were assessed for acute thrombocytopenia immediately following collections. It 
was reported that post-donation platelet counts never dropped below 100,000/μL. In all 
cases of post-donation platelet count falling below 150,000/μL the donor’s platelet count 
recovered within the 2 – 4 weeks following donation. Findings from the ALTRUYST 
trial extend our understanding of the safety of repeated apheresis platelet collections 
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beyond the context of these earlier studies documenting that donors are able to maintain 
platelet counts within the normal biological range with repeated donation. The highest 
frequency of apheresis blood donation appears safe in terms of platelet recovery and 








 Central to the safety and availability of the global blood supply is the community 
of volunteer blood donors whose altruism saves the lives of patients in need of 
transfusion. Though the collection of blood will inherently confer some risk to blood 
donors, it is essential that these risks are calibrated appropriately. In contrast to whole 
blood collections, apheresis requires the use of an anticoagulant to prevent extracorporeal 
coagulation. Citrate is the industry standard anticoagulant and functions by sequestering 
serum ionized calcium. Apheresis blood donors experience exposure to large quantities of 
citrate as the mixture of residual blood components and anticoagulant are returned 
intravenously. This exposure results in dramatic fluctuations in mineral homeostasis 
including changes serum ionized calcium, parathyroid hormone, vitamin D, and markers 
of bone metabolism. Cross-sectional studies of bone mineral density among apheresis 
blood donors drew conflicting conclusions about the impact of citrate exposure and 
skeletal health. ALTRUYST was a prospective, longitudinal, randomized, controlled trial 
testing the hypothesis that high frequency apheresis causes declines in bone density. 
Forty-one donors completed the study and there was no change in bone mineral density at 
any site measured among donors completing a median of 20 apheresis blood donations in 
the one year study period. Bone density did not change among members of the control 
group who did not undergo apheresis blood donation. Despite significant, repeated 
challenges to mineral homeostasis among apheresis blood donors, we conclude that 
current collection guidelines adequately protect the skeletal health of adult male, high 
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Dear [TITLE] [SURNAME], 
 
As part of your commitment to begin a regular apheresis blood donation program you can help BloodCenter of 
Wisconsin advance scientific understanding as part of a study. Eligible donors must be 18-65 years of age and male. If 
you choose to participate you will: 
 
• fill out a questionnaire 
• have your bone density evaluated 
• donate blood for one year 
 
Your participation will help us evaluate if regular apheresis blood donation affects bone density. Your participation will 
not have any effect on our ability to use your donated blood products for patient care. 














Instructions: Please fill in the information or place a checkmark in the bubble next to the appropriate answer for each 
question below. 
DEMOGRAPHIC INFORMATION 





 Hispanic / Latino / Spanish 
 Not Hispanic / Latino / Spanish  
 I am not sure or do not wish to answer 
Race (Check more than one if applicable): 
 White / Caucasian 
 Black / African American 
 Asian 
 American Indian / Alaska Native 
 Native Hawaiian or other Pacific Islander 





1. Are you eligible for whole blood donation?     
2. Do you have a metal prosthesis in your lumbar spine or hip?     
3. Have you experienced a bone fracture in your lumbar spine or hip?     
4. Since you turned 18 years of age, have you experienced a bone 
fracture as a result from a fall from standing height or less?     
5. Have you undergone spinal fusion surgery at your lumbar spine?     
6. Have you been diagnosed with cystic fibrosis, emphysema, celiac 
disease, and/or Chrohn’s disease?     
7. Are you willing to donate apheresis blood products 20 – 26 times over 
the next 12 month period?     
 
PERSONAL MEDICAL INFORMATION 
Have you… Yes No 
1. Smoked cigarettes at any time in the past 30 days.     
2. Smoked cigarettes at any time in the past for more than 1 continuous year.     
3. Exercised for more than 20 minutes three times per week in the past 30 days.     
4. Significantly increased or decreased your level of physical activity in the past 6 
months. 
    















   Has someone in your family been… Yes No 
1. Diagnosed with osteoporosis?     
2. Diagnosed with osteoarthritis?     
3. Diagnosed with rheumatoid arthritis?     
4. Diagnosed with kyphosis or scoliosis?     
5. Treated for a bone fracture - not caused by a trauma (i.e., accident, 
fall, etc.)?     
6. A parent was treated for a fractured hip - caused by trauma (i.e., 
accident, fall, etc.)?     
 
 
DIAGNOSIS OF MEDICAL CONDITIONS 
   Have you been diagnosed by a physician with any of the following? Yes  No 
1. Osteoporosis     
2. Osteogenesis Imperfecta      
3. Osteopenia     
4. Kyphosis      
5. Scoliosis     
6. Malnutrition     
7. Eating Disorder (Anorexia Nervosa or Bulimia)     
8. Intestinal Disorder     
9. Chronic Liver Disease     
10. Parathyroid Disease     
11. Kidney Disease/Kidney Stones     
12. Thyroid Disease (hyperthyroidism or hypothyroidism)     
13. Diabetes - Type I     
14. Diabetes - Type II                
15. Rheumatoid Arthritis     
16. Hypogonadism     
17. Other Autoimmune Disease 














   








1. Steroids or glucocorticoids (prednisone, cortisone, etc.) for more than 
three months 
      
2. Seizure medications (Dilantin, etc.) for chronic management       
3. Thyroid Hormone (Synthroid, Levothroid, Lexoxyl, etc.)       
4. Etidronate (Didronel, Didrocal)       
5. Alendronate (Fosamax)       
6. Risedronate (Actonel)       
7. Tamoxifen (Nolvadex, Istubal, Valodex)       
8. Testosterone (Androderm, Delatestryl)       
9. Nasal Calcitonin (Miacalcin)       
10. Raloxifene (Evista)       
11. Parathyroid Hormone (PTH, Forteo)       
12. Pamidronate (Aredia)       
13. Zoledronic Acid (Zometa, Reclast)       
14. Ibandronate (Boniva)        
15. Clodronate (Bonefos, Ostac)       
16. Sodium Fluoride (Fluotic)       
17. Estrogen       
18. Diabetes medication (insulin, metformin, etc.)       
19. Other Osteoporosis Medication       
              If yes, what kind: _________________________________       
 
DIET & SUPPLEMENT USE 
   Which of the following do you generally consume?  Yes No 
1. I generally consume less than 2 servings of dairy per day.     
2. I generally consume less than 2 servings of green, leafy vegetables 
per day. 
    
3. I generally consume less than 2 servings of calcium fortified food 
(such as fortified orange juice or fortified soy milk) per day. 
    
4. I generally consume less than 4 servings of vegetables per day.     
5. I drink more than 2 servings of coffee or soda per day.     
6. I drink more than 8 servings of tea per day.     
7. I drink 3 or more servings of alcohol per day.     
8. I take a vitamin D supplement (includes MVIT and liver oil). 
        If yes, how many IU per day: _____________________     
9. I take a daily calcium supplement (includes TUMS). 
        If yes, how many milligrams per day: _____________________     
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[BCW Branding]  [Marquette University Branding] 
Dear [Title] [Surname]: 
Your bone density appointment is scheduled for [TIME] on [DATE]. The Marquette University bone density 
scanner is located at 604 N. 16th St in the Department of Physical Therapy. Entrance to this building is on 16th 
street and just a few stairs up from the sidewalk. Please go to the second floor.  
 
 
You will be asked to remove any body piercing or other metal or electronic objects from your body as these 
objects interfere with the quality of the images. Please wear comfortable clothing that does not contain metal – 
not even a metal eye loop for drawstring shorts. 
First, you will lie on your back on a table for approximately 5 – 10 minutes. Then you will lie on your back while 
your legs are turned inward for 5 minutes. Finally, you will lie on your back with your legs elevated for 1 minute.  
This last scan will be repeated three times.  
You will be asked to lie still during your scans.  You will change positions for each scan.  During the scan, a 
mechanical device (the scanner) passes over your body. 
We may need to reschedule your appointment if: 
• you have a barium x-ray in the two weeks before your appointment, or; 
• you have a nuclear medicine scan in the week before your appointment, or; 
• you have an injection of x-ray dye in the week before your appointment, or; 
• you are unable to make your appointment for any reason. 
Please avoid taking any calcium supplement (including TUMS or multiple vitamins) in the two hours before your 












Dear [TITLE] [SURNAME], 
 
Thank you for enrolling in the ALTRUYST study. We have reviewed the results from your bone density scans 
taken on [DATE OF SCAN]. The purpose of this letter is to inform you that we observed bone density outside 
the expected range at one or more of the sites measured. Your individual results are indicated below.  
 
Measurement Site 
□  femoral neck  □  total hip  □  lumbar spine (L1-L4) 
 
Z-Score 
□  < (-2.0)  □  > (2.0) 
 
DXA Machine 
 □  Marquette University’s Lunar iDXA 
 
These test results are not cause for immediate concern. Bone density scans performed as part of a research 
study are not intended to make clinical diagnoses. Nevertheless, we encourage you to contact your primary 
care physician before your next routine clinical examination. Please share this notice with your primary 






Robert D. Blank, MD, PhD 
Chief, Endocrinology, Metabolism, and Clinical Nutrition 




Appendix 7 – Final Appointment Letter 
 
 
[BCW Branding] [Marquette University Branding] 
Dear [Title] [Surname]: 
Thank you for participating in the ALTRUYST study!! Your final study visit will include a suite of bone density scans 
and completion of a final questionnaire. Your bone density appointment is scheduled for [TIME] on [DATE]. The 
Marquette University bone density scanner is located at 604 N. 16th St in the Department of Physical Therapy. 
Entrance to this building is on 16th street and just a few stairs up from the sidewalk. Please go to the second floor.  
 
 
You will be asked to remove any body piercing or other metal or electronic objects from your body as these objects 
interfere with the quality of the images. Please wear comfortable clothing that does not contain metal – not even a 
metal eye loop for drawstring shorts. 
We may need to reschedule your appointment if: 
• you have a barium x-ray in the two weeks before your appointment, or; 
• you have a nuclear medicine scan in the week before your appointment, or; 
• you have an injection of x-ray dye in the week before your appointment, or; 
• you are unable to make your appointment for any reason. 
Please avoid taking any calcium supplement (including TUMS or multiple vitamins) in the two hours before your 
appointment. Please feel free to call 414-881-2130 if you have any questions. 
You will receive $50 for each of your two completed bone density visits, $100 total, to cover costs associated with 
travel. You are also eligible to receive the results of your bone density scans (both from enrollment and final visits) 
free of charge. 
Study Compliance: On [ENROLLMENT DATE] you were randomly assigned to the [GROUP NAME] group. You were 
then asked to [GROUP INSTRUCTIONS]. Our records indicate that you underwent apheresis [# APH] during the one 
year period from [ENROLLMENT DATE] through [FINAL DATE]. If you complete your final visit and have otherwise 
complied with this study’s protocol, then you will also receive [GROUP RATE]. This compensation is not tied to the 
blood donations you made during your participation in the study, but solely for the clinical assessments and 
complying with research study guidelines. 
 
We encourage study participants to continue following the progress of this study at the clinicaltrials.gov website: 
https://www.clinicaltrials.gov/ct2/show/NCT02655055.  
 
Again, thank you for your valued contribution to this research study. Please contact me with any questions that 





















Loading required package: grid 
Loading required package: lattice 
Loading required package: survival 
Loading required package: Formula 
Loading required package: ggplot2 
Attaching package: ‘Hmisc’ 
The following objects are masked from ‘package:base’: 
format.pval, round.POSIXt, trunc.POSIXt, units 
> ###extract SAS files from NHANES directory 
> ###modify location as needed 
> spinedata<-sasxport.get("C://NHANES/DATA/DXXSPN_F.XPT") 
Processing SAS dataset DXXSPN_F   .. 
> demodata<-sasxport.get("C://NHANES/DATA/DEMO_F.XPT") 
Processing SAS dataset DEMO_F   .. 
> ###visualize the variables extracted 
> names(spinedata) 
 [1] "seqn"     "dxaspnst" "dxxosbcc" "dxxl1bcc" "dxxl2bcc" "dxxl3bcc" "dxxl4bcc" "dxxosbmd" "dxxosbmc" 
"dxxosa"   "dxxl1bmd" 
[12] "dxxl1bmc" "dxxl1a"   "dxxl2bmd" "dxxl2bmc" "dxxl2a"   "dxxl3bmd" "dxxl3bmc" "dxxl3a"   "dxxl4bmd" 
"dxxl4bmc" "dxxl4a"   
[23] "dxaspnk"  "dxaspnd0" 
> names(demodata) 
 [1] "seqn"     "sddsrvyr" "ridstatr" "ridexmon" "riagendr" "ridageyr" "ridagemn" "ridageex" "ridreth1" 
"dmqmilit" "dmdborn2" 
[12] "dmdcitzn" "dmdyrsus" "dmdeduc3" "dmdeduc2" "dmdschol" "dmdmartl" "dmdhhsiz" "dmdfmsiz" 
"indhhin2" "indfmin2" "indfmpir" 
[23] "ridexprg" "dmdhrgnd" "dmdhrage" "dmdhrbr2" "dmdhredu" "dmdhrmar" "dmdhsedu" "sialang"  
"siaproxy" "siaintrp" "fialang"  
[34] "fiaproxy" "fiaintrp" "mialang"  "miaproxy" "miaintrp" "aialang"  "wtint2yr" "wtmec2yr" "sdmvpsu"  
"sdmvstra" 
> ###merge the two data files 
> m<-merge(spinedata,demodata) 
> ###visualize the merged variables 
> names(m) 
 [1] "seqn"     "dxaspnst" "dxxosbcc" "dxxl1bcc" "dxxl2bcc" "dxxl3bcc" "dxxl4bcc" "dxxosbmd" "dxxosbmc" 
"dxxosa"   "dxxl1bmd" 
[12] "dxxl1bmc" "dxxl1a"   "dxxl2bmd" "dxxl2bmc" "dxxl2a"   "dxxl3bmd" "dxxl3bmc" "dxxl3a"   "dxxl4bmd" 
"dxxl4bmc" "dxxl4a"   
[23] "dxaspnk"  "dxaspnd0" "sddsrvyr" "ridstatr" "ridexmon" "riagendr" "ridageyr" "ridagemn" "ridageex" 
"ridreth1" "dmqmilit" 
[34] "dmdborn2" "dmdcitzn" "dmdyrsus" "dmdeduc3" "dmdeduc2" "dmdschol" "dmdmartl" "dmdhhsiz" 
"dmdfmsiz" "indhhin2" "indfmin2" 
[45] "indfmpir" "ridexprg" "dmdhrgnd" "dmdhrage" "dmdhrbr2" "dmdhredu" "dmdhrmar" "dmdhsedu" 
"sialang"  "siaproxy" "siaintrp" 
[56] "fialang"  "fiaproxy" "fiaintrp" "mialang"  "miaproxy" "miaintrp" "aialang"  "wtint2yr" "wtmec2yr" 
"sdmvpsu"  "sdmvstra" 
> ###isolate variables of interest 
> ###seqn is the participant sequence number (linking variable) 
> ###riagendr=1 for male 
> ###ridreth1=3 for non-latino caucasian 
> ###ridageyr is age 
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Appendix 10 – Syntax for Power 
> ###Appendix: Proposal Simulations 1: Comparison change of
 outcome from  
> ###before to after for two groups. 
> rm(list=ls()) 
> library(MASS) 
> ###simulate test statistic under H0 
> ###set population parameters 
> ###specify muXbefore, muXafter, muYbefore and muYafter  

























> ###simulate test statistic under H0 
> Z0<-rep(NA,m) 
> for (i in 1:m){ 
+     ###Sample multivariate normal variables Xbefore and X
after 
+     X<-mvrnorm(nx,mu=c(muXafter,muXbefore),Sigma=VX) 
+     Y<-mvrnorm(ny,mu=c(muYafter,muYbefore),Sigma=VY) 
+     ###Begin an experiment and sample data with related v
ariables 
+     Xbefore<-X[,2] 
+     Ybefore<-Y[,2] 
+     Xafter<-X[,1] 
+     Yafter<-Y[,1] 
+     ###Compute change in X and change in Y 
+     XD<-Xafter-Xbefore 
+     YD<-Yafter-Ybefore 
+     ###Compute sample standard deviation of XD and YD 
+     se<-sqrt(var(XD)/nx+var(YD)/ny) 
+      
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+     ###Compute the statistic as a function of the sample 
+     Z0[i]<-(mean(XD)-mean(YD))/se 
+ } 
> ###show distribution of the test statistic under H0  
> hist(Z0,main="Distribution under H0",xlim=c(-10,10)) 
>  
> ###simulate test statistic under Ha 
> ###set population parameters 
> ###specify muXbefore, muXafter, muYbefore and muYafter  
























> ###simulate test statistic under Ha 
> Z1<-rep(NA,m) 
> for (i in 1:m){ 
+     X<-mvrnorm(nx,mu=c(muXafter,muXbefore),Sigma=VX) 
+     Y<-mvrnorm(ny,mu=c(muYafter,muYbefore),Sigma=VY) 
+     ###Begin an experiment and sample data with related v
ariables 
+     Xbefore<-X[,2] 
+     Ybefore<-Y[,2] 
+     Xafter<-X[,1] 
+     Yafter<-Y[,1] 
+     ###Compute change in X and change in Y 
+     XD<-Xafter-Xbefore 
+     YD<-Yafter-Ybefore 
+     ###Compute sample standard deviation of XD and YD 
+     se<-sqrt(var(XD)/nx+var(YD)/ny) 
+      
+     ###Compute the statistic as a function of the sample 
+     Z1[i]<-(mean(XD)-mean(YD))/se 
+ } 
> ###show distribution of the test statistic under Ha 
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> hist(Z1,main="Distribution under Ha",xlim=c(-10,10)) 
>  
> ###obtain critical value 
> c<-quantile(Z0,probs=1-alpha) 
> quantile(Z0,probs=1-alpha) 
     95%  
1.720837  
>  















##Identify Working Directory 
data<-read.xlsx2("M:/Staff/W Bialkowski/PhD 
Marquette/ALTRUYST/Analysis/ALTRUYST Analytic Data 
Set.xlsx", 
                2, 
                as.data.frame=TRUE, 
                header=TRUE, 
                keepFormulas=FALSE, 
                colClasses=c(rep("numeric",55))) 
 






















































































hist.default(data$age, xlab="Age (years)", 
main="Distribution of Age") 
hist.default(data$height, xlab="Height (inches)", 
main="Distribution of Height") 
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hist.default(data$weight, xlab="Weight (pounds)", 
main="Distribution of Weight") 




hist.default(data$Na, xlab="Serum Sodium (mmol/L)", 
main="Distribution of Serum Sodium") 
hist.default(data$K, xlab="Serum Potassium (mmol/L)", 
main="Distribution of Serum Potassium") 
hist.default(data$Cl, xlab="Serum Chloride (mmol/L))", 
main="Distribution of Serum Chloride") 
hist.default(data$CO2, xlab="Serum CO2 (mmol/L)", 
main="Distribution of Serum CO2") 
 
par(mfrow=c(2,2)) 
hist.default(data$anion, xlab="Anion Gap (mmol/L)", 
main="Distribution of Anion Gap") 
hist.default(data$urea, xlab="Urea (mg/dL)", 
main="Distribution of Urea") 
hist.default(data$creat, xlab="Serum Creatinine (mg/dL)", 
main="Distribution of Serum Creatinine") 
hist.default(data$gluc, xlab="Serum Glucose (mg/dL)", 
main="Distribution of Serum Glucose") 
 
par(mfrow=c(2,2)) 
hist.default(data$alkphos, xlab="Alkaline Phosphatase 
(U/L)", main="Distribution of Alkaline Phosphatase") 
hist.default(data$ALT, xlab="ALT (U/L)", main="Distribution 
of ALT") 
hist.default(data$AST, xlab="AST (U/L)", main="Distribution 
of AST") 
hist.default(data$Ca, xlab="Serum Calcium (mg/dL)", 
main="Distribution of Serum Calcium") 
 
par(mfrow=c(2,2)) 
hist.default(data$P, xlab="Serum Phosphorous (mg/dL)", 
main="Distribution of Serum Phosphorous") 
hist.default(data$prot, xlab="Serum Protein (g/dL)", 
main="Distribution of Serum Protein") 
hist.default(data$alb, xlab="Serum Albumin (g/dL)", 
main="Distribution of Serum Albumin") 
hist.default(data$bili, xlab="Serum Bilirubin (mg/dL)", 
main="Distribution of Serum Bilirubin") 
 
par(mfrow=c(2,2)) 
hist.default(data$test, xlab="Male Adult Testosterone 
(ng/dL)", main="Distribution of Testosterone") 
hist.default(data$pre_L1_4, xlab="Pre Lumbar Spine 
(g/cm^2)", main="Distribution of Pre Lumbar Spine") 
hist.default(data$pre_TH, xlab="Pre Total Hip (g/cm^2)", 






hist.default(data$anion, xlab="Anion Gap before 
transformation", main="Distribution of Anion Gap") 
hist.default(log(data$anion), xlab="Anion Gap after 
transformation", main="Distribution of Anion Gap") 
hist.default(data$alkphos, xlab="Alkaline Phosphatase 
before transformation", main="Distribution of Alkaline 
Phosphatase") 
hist.default(log(data$alkphos), xlab="Alkaline Phosphatase 
after transformation", main="Distribution of Alkaline 
Phosphatase") 
hist.default(data$bili, xlab="Bilirubin before 
transformation", main="Distribution of Bilirubin") 
hist.default(log(data$bili), xlab="Bilirubin after 
transformation", main="Distribution of Bilirubin") 
 





##Test for differences 



























##visualize distributions of BMD at enrollment 
par(mfrow=c(3,2)) 
hist(data$pre_L1_4,xlim = c(0.9,1.5),ylim=c(0,12)) 
hist(data$pre_TH,xlim = c(0.8,1.5),ylim=c(0,12)) 
hist(msubC$pre_L1_4,xlim = c(0.9,1.5),ylim=c(0,6)) 
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hist(msubC$pre_TH,xlim = c(0.8,1.5),ylim=c(0,6)) 
hist(msubT$pre_L1_4,xlim = c(0.9,1.5),ylim=c(0,12)) 
hist(msubT$pre_TH,xlim = c(0.8,1.5),ylim=c(0,12)) 
 
##Visualize BMD at enrollment for Both Groups 
##there's a number of ways I'm considering illustrating 
these 
##this is an example 
ggplot(data, aes(x=test)) +  
  geom_density(aes(stat="density"), 
                 binwidth=0.5, 
                 colour="black",  
                 fill="white") + 




                 y=pre_TH))+ 
       geom_point(size=1.5, shape=21, fill="white")+ 
       labs(title="Baseline TH BMD, Both Groups") 
 
ggplot(data, aes(x=SubjectID, 
                 y=pre_L1_4)) 
       + ggtitle("Baseline L Spine BMD, Both Groups") 
 
##Visualize BMD at enrollment for Controls 
##Visualize BMD at enrollment for Treatment 
##Visualize Final BMD for Both Groups 
##Visualize Final BMD for Controls 
##Visualize Final BMD for Treatment 
 












































































































##compare mean change to LSC in treated 
##LSC at lumbar spine is 0.00743 
if((mean(deltaL1_4T))>0.00743) 
  print("mean change among treated subjects exceeds LSC for 
lumbar spine in the positive direction") 
if((mean(deltaL1_4T))<(-0.00743)) 
  print("mean change among treated subjects exceeds LSC for 
lumbar spine in the negative direction") 
 
##LSC at TH is 0.00671 
if((mean(deltaTHT))>0.00671) 
  print("mean change for treated subjects exceeds LSC for 
total hip in the positive direction") 
if((mean(deltaTHT))<(-0.00671)) 
  print("mean change for treated subjects exceeds LSC for 
total hip in the negative direction") 
 
##compare mean change to LSC in controls 
##LSC at lumbar spine is 0.00743 
if((mean(deltaL1_4C))>0.00743) 
  print("mean change among control subjects exceeds LSC for 
lumbar spine in the positive direction") 
if((mean(deltaL1_4C))<(-0.00743)) 
  print("mean change among control subjects exceeds LSC for 
lumbar spine in the negative direction") 
 




  print("mean change for control subjects exceeds LSC for 
total hip in the positive direction") 
if((mean(deltaTHC))<(-0.00671)) 
  print("mean change for control subjects exceeds LSC for 
total hip in the negative direction") 
 











##Boxplots change in BMD 
par(mfrow=c(2,2)) 
boxplot(deltaL1_4C, ylim=c(-0.1,0.1),main="L spine 
control") 
boxplot(deltaL1_4T, ylim=c(-0.1,0.1),main="L spine 
treated") 
boxplot(deltaTHC, ylim=c(-0.05,0.05),main="hip control") 
boxplot(deltaTHT, ylim=c(-0.05,0.05),main="hip treated") 
 
##create Figure 3 for main paper - box plots 
ggplot(data, aes(x=factor(apheresis), y=deltaL1_4))+ 
  ylim(-0.06,0.06)+ 
  geom_boxplot()+ 
  theme_bw()+ 




  theme(panel.border = element_blank(),  
        panel.grid.major = element_blank(), 
        panel.grid.major.y = element_line(linetype = 
"dashed", colour = "black"), 
        panel.grid.minor = element_blank(),  
        panel.background = element_blank(), 
        axis.line = element_line(colour = "white")) 
 
ggplot(data, aes(x=factor(apheresis), y=deltaTH))+ 
  ylim(-0.06,0.06)+ 
  geom_boxplot()+ 
  theme_bw()+ 




  theme(panel.border = element_blank(),  
        panel.grid.major = element_blank(), 
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        panel.grid.major.y = element_line(linetype = 
"dashed", colour = "black"), 
        panel.grid.minor = element_blank(),  
        panel.background = element_blank(), 
        axis.line = element_line(colour = "white")) 
 
##Define Number of Subjects Analyzed in Each Group 
nC<-15 
nT<-26 
   
##BEGIN: Unadjusted Analysis 





































  print("reject the null hypothesis for total hip") 
if((TTH-qtTH)<=0) 






  print("reject the null hypothesis for lumbar spine") 
if((TL1_4-qtL1_4)<=0) 
  print("you are not able to reject the null hypothesis for 
lumbar spine") 
 
##test for difference in proportions 
LspineI<-matrix(c(8,7,13,13),byrow=TRUE, 2, 2) 
LspineI 
chisq.test(LspineI, correct = FALSE) 
LspineD<-matrix(c(5,10,8,18),byrow=TRUE, 2, 2) 
LspineD 
chisq.test(LspineD, correct = FALSE) 
THI<-matrix(c(6,9,6,20),byrow=TRUE, 2, 2) 
THI 
chisq.test(THI, correct = FALSE) 
THD<-matrix(c(3,12,11,15),byrow=TRUE, 2, 2) 
THD 
chisq.test(THD, correct = FALSE) 
 
##END: Unadjusted Analysis 
 
##BEGIN Adjusted Analysis Using Multivariable Linear 
Regression 
##visualize distributions of participant demographic and 
behavioral characteristics 
##can also do str function for each predictor to examine 
potential extreme values 
##can also do stem and leaf plots 
##can do scatterplots to evaluate need for transformations 
##can also test for correlations using Pearsons/Spearmans  
##can test linearity using Shapiro-Wilk's 
##can evaluate leverage values 
##can do QQ plots 
##can do Jackknife Residuals 
##can do Cook's Distance 
##can evaluate collinearity with rcorr function 
##can do Variance Inflation Factors (VIF>10 interrogation) 
##can evaluate multicollinearity with Tolerance Values, 









##negative change in L spine 
fitnL1_4<-lm(data$bigndeltaL1_4~ 
          (data$apheresis)+ 
          (data$age)+ 
          (as.factor(data$risks))+ 
          (as.factor(data$family))+ 
          (as.factor(data$conditions))+ 
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          (as.factor(data$medications))+ 
          (as.factor(data$diet))+ 
          (data$BMI)+ 
          (data$pre_L1_4)+ 
          (data$Na)+ 
          (data$K)+ 
          (data$Cl)+ 
          (data$CO2)+ 
          (data$anion)+ 
          (data$urea)+ 
          (data$creat)+ 
          (data$gluc)+ 
          (data$alkphos)+ 
          (data$AST)+ 
          (data$ALT)+ 
          (data$Ca)+ 
          (data$P)+ 
          (data$prot)+ 
          (data$alb)+ 
          (data$bili)+ 
          (data$test)) 
summary(fitnL1_4) 
anova(fitnL1_4) 





##positive change in L spine 
fitpL1_4<-lm(data$bigpdeltaL1_4~ 
               (data$apheresis)+ 
               (data$age)+ 
               (as.factor(data$risks))+ 
               (as.factor(data$family))+ 
               (as.factor(data$conditions))+ 
               (as.factor(data$medications))+ 
               (as.factor(data$diet))+ 
               (data$BMI)+ 
               (data$pre_L1_4)+ 
               (data$Na)+ 
               (data$K)+ 
               (data$Cl)+ 
               (data$CO2)+ 
               (data$anion)+ 
               (data$urea)+ 
               (data$creat)+ 
               (data$gluc)+ 
               (data$alkphos)+ 
               (data$AST)+ 
               (data$ALT)+ 
               (data$Ca)+ 
               (data$P)+ 
               (data$prot)+ 
               (data$alb)+ 
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               (data$bili)+ 
               (data$test)) 
summary(fitpL1_4) 
anova(fitpL1_4) 





##negative change in total hip 
fitnTH<-lm(data$bigndeltaTH~ 
               (data$apheresis)+ 
               (data$age)+ 
               (as.factor(data$risks))+ 
               (as.factor(data$family))+ 
               (as.factor(data$conditions))+ 
               (as.factor(data$medications))+ 
               (as.factor(data$diet))+ 
               (data$BMI)+ 
               (data$pre_TH)+ 
               (data$Na)+ 
               (data$K)+ 
               (data$Cl)+ 
               (data$CO2)+ 
               (data$anion)+ 
               (data$urea)+ 
               (data$creat)+ 
               (data$gluc)+ 
               (data$alkphos)+ 
               (data$AST)+ 
               (data$ALT)+ 
               (data$Ca)+ 
               (data$P)+ 
               (data$prot)+ 
               (data$alb)+ 
               (data$bili)+ 
               (data$test)) 
summary(fitnTH) 
anova(fitnTH) 





##positive change in TH 
fitpTH<-lm(data$bigpdeltaTH~ 
             (data$apheresis)+ 
             (data$age)+ 
             (as.factor(data$risks))+ 
             (as.factor(data$family))+ 
             (as.factor(data$conditions))+ 
             (as.factor(data$medications))+ 
             (as.factor(data$diet))+ 
             (data$BMI)+ 
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             (data$pre_TH)+ 
             (data$Na)+ 
             (data$K)+ 
             (data$Cl)+ 
             (data$CO2)+ 
             (data$anion)+ 
             (data$urea)+ 
             (data$creat)+ 
             (data$gluc)+ 
             (data$alkphos)+ 
             (data$AST)+ 
             (data$ALT)+ 
             (data$Ca)+ 
             (data$P)+ 
             (data$prot)+ 
             (data$alb)+ 
             (data$bili)+ 











##Everything prior was the intention to treat analysis 
##we can now perform the same analyses limited to protocol 
compliers 
##i.e. ITT=1 in the data set 
















##Identify Working Directory 
data<-read.xlsx2("M:/Staff/W Bialkowski/PhD 
Marquette/ALTRUYST/Analysis/ALTRUYST Analytic Data Set 
compliers.xlsx", 
                2, 
                as.data.frame=TRUE, 
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                header=TRUE, 
                keepFormulas=FALSE, 
                colClasses=c(rep("numeric",68))) 
 




















































































##Test for differences 








































##Visualize BMD at enrollment for Both Groups 
##there's a number of ways I'm considering illustrating 
these 
##this is an example 
ggplot(data, aes(x=test)) +  
  geom_density(aes(stat="density"), 
                 binwidth=0.5, 
                 colour="black",  
                 fill="white") + 




                 y=pre_TH))+ 
       geom_point(size=1.5, shape=21, fill="white")+ 
       labs(title="Baseline TH BMD, Both Groups") 
 
ggplot(data, aes(x=SubjectID, 
                 y=pre_L1_4)) 
       + ggtitle("Baseline L Spine BMD, Both Groups") 
 
##Visualize BMD at enrollment for Controls 
##Visualize BMD at enrollment for Treatment 
##Visualize Final BMD for Both Groups 
##Visualize Final BMD for Controls 
##Visualize Final BMD for Treatment 
 









































































##Boxplots change in BMD 
par(mfrow=c(2,2)) 
boxplot(deltaL1_4C, ylim=c(-0.1,0.1),main="L spine 
control") 
boxplot(deltaL1_4T, ylim=c(-0.1,0.1),main="L spine 
treated") 
boxplot(deltaTHC, ylim=c(-0.05,0.05),main="hip control") 
boxplot(deltaTHT, ylim=c(-0.05,0.05),main="hip treated") 
 
##create Figure 3 for main paper - box plots 
ggplot(data, aes(x=factor(apheresis), y=deltaL1_4))+ 
  ylim(-0.06,0.06)+ 
  geom_boxplot()+ 
  theme_bw()+ 




  theme(panel.border = element_blank(),  
        panel.grid.major = element_blank(), 
        panel.grid.major.y = element_line(linetype = 
"dashed", colour = "black"), 
        panel.grid.minor = element_blank(),  
        panel.background = element_blank(), 
        axis.line = element_line(colour = "white")) 
 
ggplot(data, aes(x=factor(apheresis), y=deltaTH))+ 
  ylim(-0.06,0.06)+ 
  geom_boxplot()+ 
  theme_bw()+ 




  theme(panel.border = element_blank(),  
        panel.grid.major = element_blank(), 
        panel.grid.major.y = element_line(linetype = 
"dashed", colour = "black"), 
        panel.grid.minor = element_blank(),  
        panel.background = element_blank(), 
        axis.line = element_line(colour = "white")) 
 
##compare mean change to LSC in treated 
##LSC at lumbar spine is 0.00743 
if((mean(deltaL1_4T))>0.00743) 
  print("mean change among treated subjects exceeds LSC for 




  print("mean change among treated subjects exceeds LSC for 
lumbar spine in the negative direction") 
 
##LSC at TH is 0.00671 
if((mean(deltaTHT))>0.00671) 
  print("mean change for treated subjects exceeds LSC for 
total hip in the positive direction") 
if((mean(deltaTHT))<(-0.00671)) 
  print("mean change for treated subjects exceeds LSC for 
total hip in the negative direction") 
 
##compare mean change to LSC in controls 
##LSC at lumbar spine is 0.00743 
if((mean(deltaL1_4C))>0.00743) 
  print("mean change among control subjects exceeds LSC for 
lumbar spine in the positive direction") 
if((mean(deltaL1_4C))<(-0.00743)) 
  print("mean change among control subjects exceeds LSC for 
lumbar spine in the negative direction") 
 
##LSC at TH is 0.00671 
if((mean(deltaTHC))>0.00671) 
  print("mean change for control subjects exceeds LSC for 
total hip in the positive direction") 
if((mean(deltaTHC))<(-0.00671)) 
  print("mean change for control subjects exceeds LSC for 
total hip in the negative direction") 
 
##Define Number of Subjects Analyzed in Each Group 
nC<-15 
nT<-21 
   
##BEGIN: Unadjusted Analysis 







































  print("reject the null hypothesis for total hip") 
if((TTH-qtTH)<=0) 




  print("reject the null hypothesis for lumbar spine") 
if((TL1_4-qtL1_4)<=0) 
  print("you are not able to reject the null hypothesis for 
lumbar spine") 
 
##END: Unadjusted Analysis 
 
##BEGIN Adjusted Analysis Using Multivariable Linear 
Regression 
##visualize distributions of participant demographic and 
behavioral characteristics 
##can also do str function for each predictor to examine 
potential extreme values 
##can also do stem and leaf plots 
##can do scatterplots to evaluate need for transformations 
##can also test for correlations using Pearsons/Spearmans  
##can test linearity using Shapiro-Wilk's 
##can evaluate leverage values 
##can do QQ plots 
##can do Jackknife Residuals 
##can do Cook's Distance 
##can evaluate collinearity with rcorr function 
##can do Variance Inflation Factors (VIF>10 interrogation) 
##can evaluate multicollinearity with Tolerance Values, 












##negative change in L spine 
fitnL1_4<-lm(data$bigndeltaL1_4~ 
               (data$apheresis)+ 
               (data$age)+ 
               (as.factor(data$risks))+ 
               (as.factor(data$family))+ 
               (as.factor(data$conditions))+ 
               (as.factor(data$medications))+ 
               (as.factor(data$diet))+ 
               (data$BMI)+ 
               (data$pre_L1_4)+ 
               (data$Na)+ 
               (data$K)+ 
               (data$Cl)+ 
               (data$CO2)+ 
               (data$anion)+ 
               (data$urea)+ 
               (data$creat)+ 
               (data$gluc)+ 
               (data$alkphos)+ 
               (data$AST)+ 
               (data$ALT)+ 
               (data$Ca)+ 
               (data$P)+ 
               (data$prot)+ 
               (data$alb)+ 
               (data$bili)+ 
               (data$test)) 
summary(fitnL1_4) 
anova(fitnL1_4) 





##positive change in L spine 
fitpL1_4<-lm(data$bigpdeltaL1_4~ 
               (data$apheresis)+ 
               (data$age)+ 
               (as.factor(data$risks))+ 
               (as.factor(data$family))+ 
               (as.factor(data$conditions))+ 
               (as.factor(data$medications))+ 
               (as.factor(data$diet))+ 
               (data$BMI)+ 
               (data$pre_L1_4)+ 
               (data$Na)+ 
               (data$K)+ 
               (data$Cl)+ 
               (data$CO2)+ 
               (data$anion)+ 
               (data$urea)+ 
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               (data$creat)+ 
               (data$gluc)+ 
               (data$alkphos)+ 
               (data$AST)+ 
               (data$ALT)+ 
               (data$Ca)+ 
               (data$P)+ 
               (data$prot)+ 
               (data$alb)+ 
               (data$bili)+ 
               (data$test)) 
summary(fitpL1_4) 
anova(fitpL1_4) 





##negative change in total hip 
fitnTH<-lm(data$bigndeltaTH~ 
             (data$apheresis)+ 
             (data$age)+ 
             (as.factor(data$risks))+ 
             (as.factor(data$family))+ 
             (as.factor(data$conditions))+ 
             (as.factor(data$medications))+ 
             (as.factor(data$diet))+ 
             (data$BMI)+ 
             (data$pre_TH)+ 
             (data$Na)+ 
             (data$K)+ 
             (data$Cl)+ 
             (data$CO2)+ 
             (data$anion)+ 
             (data$urea)+ 
             (data$creat)+ 
             (data$gluc)+ 
             (data$alkphos)+ 
             (data$AST)+ 
             (data$ALT)+ 
             (data$Ca)+ 
             (data$P)+ 
             (data$prot)+ 
             (data$alb)+ 
             (data$bili)+ 
             (data$test)) 
summary(fitnTH) 
anova(fitnTH) 









             (data$apheresis)+ 
             (data$age)+ 
             (as.factor(data$risks))+ 
             (as.factor(data$family))+ 
             (as.factor(data$conditions))+ 
             (as.factor(data$medications))+ 
             (as.factor(data$diet))+ 
             (data$BMI)+ 
             (data$pre_TH)+ 
             (data$Na)+ 
             (data$K)+ 
             (data$Cl)+ 
             (data$CO2)+ 
             (data$anion)+ 
             (data$urea)+ 
             (data$creat)+ 
             (data$gluc)+ 
             (data$alkphos)+ 
             (data$AST)+ 
             (data$ALT)+ 
             (data$Ca)+ 
             (data$P)+ 
             (data$prot)+ 
             (data$alb)+ 
             (data$bili)+ 






















































Appendix 15 – DXA Quality Control Records 
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